

*Fifth Edition*

# *First Principles of Gastroenterology*

The Basis of Disease and an Approach to Management

5



JANSSEN-ORTHO

*A.B.R. Thomson and  
E.A. Shaffer, editors*

# Index

The bold letter **t** or **f** following a page reference indicates that the information appears on that page only in a table or figure, respectively.

- abdomen: examination of, 41–8; regions, 43**f**
- abdominal aortic reconstruction, 275**t**
- abdominal mass: about, 37–40; with colon cancer, 365**t**; and constipation, 386; with Crohn's disease, 314, 342**t**; with cystic fibrosis, 456; GI tract, 307, 373, 375, 379; with hepatocellular carcinoma, 647; in pancreas, 434, 445; with ulcerative colitis, 342**t**
- abetalipoproteinemia, 194, 201**t**
- abscesses: amebic, 392; anorectal, 397, 399, 406–7; appendiceal, 320**t**; colonic, 391; crypt, 285, 331, 332**f**; diverticular, 253; and diverticulitis, 373; eosinophilic, 114; horseshoe, 406; liver, 474; lung, 113; pancreatic, 434; pararectal, 316**t**; perianal, 344**t**
- absorption: of carbohydrates, 194–9, 227–8; in colon, 360, 362–4; of electrolytes, 185–92, 333; of fat, 192–4; of glucose, 194**f**; principles of, 178; of protein, 199–202; of vitamins and minerals, 178–83; of water, 183–5, 360
- acanthosis, glycogen, esophageal, 126**t**
- acanthosis nigricans, 126
- ACE inhibitors. *see* angiotensin converting enzyme (ACE) inhibitors
- acetaminophen, 523**t**, 524, 525**t**, 570, 581–2, 631
- acetate, 350, 362
- acetic acid, 199, 245
- acetylcholine, 145, 190**t**
- acetyl-CoA, 53
- N-acetylcysteine, 582
- achalasia, 118**f**; about, 121–2; cricopharyngeal, 117**t**, 118; esophageal, 6–8, 14, 96, 118**f**, 120**f**; and gas, 14; and Hirschsprung's disease, 388; vigorous, 121–2
- achlorhydria, 57**t**, 217, 245**t**, 451
- acid perfusion test, 98, 106**t**
- acid suppressants, 145
- acidosis: children, 687**t**, 689, 698, 715, 727**t**, 729; cirrhosis, 571, 591; ischemia, 253, 266; liver transplantation, 641; pancreatitis, 433**t**; ulcerative colitis, 335
- acids (chemicals), 115
- acinar cells, 56, 418–19, 422
- acquired immunodeficiency syndrome. *see* AIDS
- acrodermatitis enteropathica, 205**t**
- actinomycosis, 149
- acute abdomen, 24–7
- acute mesenteric ischemia, 252–4
- acyclovir, 294**t**, 301, 653
- acyclovir treatment, 114
- acyl-CoA-carnitine acyltransferase, 54
- adalimumab, 328
- Addison's disease, 21**t**, 150, 520
- adefovir, 558
- adenine, in gene sequences, 741
- adenocarcinoma: bile duct, 486; chronic

- diarrhea, 21t; colon, 366; with Crohn's disease, 318; esophagus, 105, 112, 125, 126t, 127; gallbladder, 479–80; gastric, 152t, 168; small intestine, 255; with ulcerative colitis, 343
- adenoid cystic carcinoma, 126t
- adenoma: bile duct, 486; colon, 20, 367f; causing diarrhea, 20, 21t, 229; drug-induced, 579, 580t; hepatic, 584–5; hepatocellular, 644; liver, 583t; small intestine, 255; stomach, 369
- adenomyosis, 479
- adenosquamous carcinoma, 126t
- S-adenosylmethionine, 655
- adenovirus, 530, 634t, 642
- adenylate cyclase, 214–15, 230, 712
- adhesions, colonic, 376t, 377
- adrenal gland, 140
- adrenal insufficiency, 235t, 457
- adrenocorticosteroids, 190
- aeromonas hydrophila, 341t
- aerophagia, 13–15
- afferent loop stasis, 201t
- aflatoxins, 55t, 647
- age factors: cholelithiasis, 464t; colitis, 224; colon cancer, 364, 366, 368; colorectal cancer, 335, 398, 404; diverticulosis, 372; gallstone, 464t; gastric cancer, 9, 170; H. pylori, 147; hepatitis B, 559t; Hirschsprung's disease, 700t; liver disease, 552, 556t, 562t, 635t; pancreatic disease, 426, 431t, 437, 444; serious GI events, 160t; ulcerative colitis, 334, 353; upper GI bleeding, 37; vomiting, 686, 687t
- AIDS: about, 289; and acalculous cholecystitis, 477–8; and anorectal infection, 407; and cholestasis, 590; diagnosis, 290–1, 296, 298–9, 305; and diarrhea, 21t, 22, 222; and herpes, 408; and mycobacterial avium-intracellulare (MAI), 292; and Salmonella, 389–90
- AIDS cholangiopathy, 304
- air embolism, 75
- Alagille's syndrome, 482, 731–2
- alanine aminotransferase, 505, 513
- albendazole, 294t, 299, 394
- albumin, 32–3, 66–7, 248–9, 321, 506, 601t, 618, 632
- Alcock's canal, 396
- alcohol: causing acute hepatitis, 530t; causing ascites, 48; Boerhaave's syndrome, 134; and celiac disease, 61–2; and diarrhea, 21t, 22; effects on liver, 55t; folate deficiency, 179; causing gastritis, 146, 151; and GI bleeding, 36, 165; and HIV, 304; and malassimilation, 207; causing malnutrition, 23; causing pancreatitis, 430t, 431, 437, 445; causing squamous cell carcinoma, 128
- alcohol withdrawal, 11, 572
- alcohol–drug interactions, acetaminophen, 570
- alcoholic hepatitis: cause, 55t; clinical features, 569–71; diagnosis, 566t, 567; management, 572–3; causing portal hypertension, 602t, 603
- alcoholic lipemia, 507
- alcoholic liver disease: about, 517, 567–9; cirrhosis, 571–2; clinical features, 501, 504; fatty liver, 569; hepatitis, 569–71; management, 572–4
- aldosterone, 32, 187, 190, 361
- alendronate sodium, 116
- ALG, 639
- alginates, 109, 195
- alkaline phosphatase tests, 506
- alkalis, 115
- alkalosis, 617, 627
- allograft rejection, 641–2
- almitrine bismesylate, 612
- aloe, 232
- alopecia, 205t
- alosetron, 382t
- alpha<sub>1</sub>-antitrypsin deficiency: about, 520; and cirrhosis, 597, 598t; clinical features, 731; and inherited liver disease, 585
- alpha-adrenergic agonists, 231
- alpha-fetoprotein test, 508
- aluminum hydroxide, 243
- amanita, 430t
- amebiasis, 22, 221–2, 320t, 321, 341t
- ameboma, 391
- amenorrhea, 203t, 502t, 566
- amikacin, 293t
- amiloride, 187, 617
- amino acids: absorption, 185–6, 199–200, 202; aromatic, 625; branched-chain, 628; catabolism, 494; dietary therapy, 63; enteral formulas, 71–2; malnutrition, 55–6; supplements, 573; total parenteral nutrition (TPN), 73
- aminoglycosides, 217, 622
- aminosalicylic acid, 246
- 5-aminosalicylic acid mesalazine. *see* mesalamine
- aminotransferases, 471, 474, 505–6, 513–21, 548, 555, 571–2, 591, 600. *see also* transaminases

- amiodarone, 576, 584  
 ammonia, 245, 494, 625  
 amoxicillin, 216, 582, 621  
 amphotericin B, 113, 293t, 296–7  
 ampicillin, 216, 389, 392, 476  
 amylase, 56, 195, 199, 305, 427–8, 442, 446, 471  
 amyloidosis, 117t, 201t, 275t, 278f, 316t, 321, 344t, 645  
 amylopectin, 195  
 amylose, 195  
 amyotrophic lateral sclerosis, 117t  
 anabolic hormone, 50  
 anabolism, 75  
 anaerobes, 198f, 476  
 anaerobic streptococci, 244  
 anal canal: anatomy, 395–6; carcinoma, 303; examination of, 399–402; fistula-abscess disease, 406; fistulas, 303, 344t, 399; hemorrhoids, 402; presenting complaints, 396–9; venereal warts, 407  
 anal sphincter: anatomy, 381, 395–6; defecation, 383f, 386; and fecal incontinence, 381–4; spasm, 403  
 analgesics, 389; to treat cholecystitis, 472; to treat cholelithiasis, 465; to treat hemorrhoids, 403; to treat herpes, 408; to treat ischemia, 286; to treat pancreatitis, 436, 441; to treat Shigella, 389  
 anaphylaxis, 275t  
 anastomosis: Billroth, 146f, 151; in gastrectomy, 170–1; ileoanal, 353; Roux-en-Y, 482; small intestine, 482  
 anemia. *see also* iron deficiency; with abdominal pain, 29; and alcoholic cirrhosis, 572; aplastic, 547; with cancer, 255; and celiac disease, 235t, 237; children, 684, 689, 693, 694t, 706t; and cholelithiasis, 464t; and cirrhosis, 600; with Crohn's disease, 314; and diagnosis, 4; causing diarrhea, 20; and GI bleeding, 34; hemolytic, 217, 317t, 344t, 347; and hiatus hernia, 103; hypochromic microcytic, 206; in inflammatory bowel disease, 316t–17t, 318, 321, 333–5 *passim*, 340, 344t–5t, 347; iron deficiency, 317t, 365t, 366, 380; in ischemia, 285; and malabsorption, 204t, 208–9; and malnutrition, 23; megaloblastic, 317t; normochromic, normocytic-type, 321; pernicious, 57t, 144t, 150, 182t; with toxic megacolon, 340, 345t; with ulcerative colitis, 333, 335, 344t; vitamin B<sub>12</sub> deficiency, 205t  
 aneurysm: abdominal, 26; aortic, 24–5  
 angina, 35, 254  
 angiodysplasia, 34, 35t, 165, 410, 412, 413t  
 angioedema, 547  
 angiography, 253, 268, 276  
 angioma, 255  
 angiomatosis, 302  
 angioplasty, 253  
 angiosarcoma, 55t, 585, 634t  
 angiotensin converting enzyme (ACE) inhibitors, 287  
 angular mouth fissure, 23  
 animoacidurias, 200  
 anisakiasis, 320t  
 anismus, 388  
 ankylosing spondylitis, 316t, 319, 335, 344t, 347  
 anorectal manometry, 18  
 anorectal spaces, 396  
 anorexia: about, 12–13; and acute abdomen, 25; and alcoholic liver disease, 570; and ascites, 33; and celiac disease, 235; cholecystitis, 471; with Crohn's disease, 315t; and diarrhea, 219; drug-induced, 350; and hepatocellular carcinoma, 647; with HIV, 305; inflammatory bowel disease, 64t; and jaundice, 31; in liver disease, 501, 502t; marasmus, 56; nutritional intervention, 70; and protein deficiency, 206; with ulcerative colitis, 334; vitamin deficiency, 57t  
 anoscopy, 401–2  
 antacids: causing diarrhea, 20, 213t, 225, 226t; to treat esophagitis, 114; to treat GERD, 109; magnesium-containing, 225, 227t; to treat pancreatitis, 442  
 antiarrhythmics, 225  
 antibiotics: to treat bacterial overgrowth, 208t, 248, 252; to treat bile duct disease, 480; to treat biliary atresia, 731; to treat *C. difficile*, 390; to treat cancer, 255; to treat cholangitis, 483–4, 594; to treat cholecystitis, 472; to treat choledocholithiasis, 476; and cirrhosis, 600; to treat colitis, 224; to treat Crohn's disease, 323, 329; to treat cystic fibrosis, 454; causing diarrhea, 213t; to treat diarrhea, 218; causing diarrhea, 223–4, 233t; to treat diarrhea, 715, 718; to treat diverticulitis, 373; to treat gastroenteritis, 215; to treat *H. pylori* infection, 149; to treat hepatic encephalopathy, 628; causing hepatitis, 518, 551t; to treat HIV-related infections, 292; causing

- hyperbilirubinemia, 727t; to treat inflammatory bowel disease, 340; to treat ischemia, 269, 286; and liver transplantation, 639; to treat pancreatitis, 436; to treat peritonitis, 622–3; to treat PUD, 164; to treat Salmonella, 389; to treat Shigella, 213t, 389; to treat spontaneous bacterial peritonitis, 623; to treat strongyloides stercoralis, 394; to treat ulcerative colitis, 352–3; to treat Whipple's disease, 208t, 251
- anticholinergics: causing constipation, 17, 698; causing esophagitis, 115; to treat gastropathies, 152; to treat GERD, 109; to treat H. pylori infection, 173; to treat irritable bowel syndrome, 382t; and ulcerative colitis, 348
- anticoagulants, 36
- antidepressants, 124, 382t, 525t
- antifungal agents, 296
- antihistamines, 11
- antihypertensives, 17
- anti-inflammatory agents, 116, 275t, 279, 341t
- antilymphocyte products, 639
- antimetabolites, 225
- antimicrobials, 215, 246, 329–30
- antimitochondrial antibody tests, 507, 521
- antimotility agents, 382t, 389, 394
- antinuclear factor test, 507
- antiproteases, 420
- antiretroviral drugs, 291, 300, 304, 306
- antismooth muscle antibody test, 507
- antithrombin C disease, 275t
- antithymocyte globulin, 641
- antituberculous drugs, 295, 518
- antral G-cell hyperfunction, 144t
- antrum, retained, 144t
- anxiety, 30
- aortic aneurysm, 24
- aorto-SMA graft, 254
- aortovisceral bypass, 276
- apathy, 624
- aperistalsis, 121
- apnea, 694
- apolipoproteins, 53, 193
- apoprotein, 55, 494
- apoptosis, 313t, 314, 328, 748, 752
- appendicitis, 27, 29, 216, 320t
- appendix: appendicitis, 27, 29, 216, 320t; carcinoid tumors, 250
- appetite, 12, 203t
- arachidonic acid, 74, 161
- areflexia, 58t
- arginine, 745
- arsenicals, 584
- arterial desaturation, 502t, 504
- arterial reconstruction, 271
- arteriography, 37
- arthralgia, 95, 251, 588
- arthritis: and Crohn's disease, 319; and gastric secretions, 161; with hepatitis, 547, 566; and inflammatory bowel disease, 316t, 319, 335, 344t, 347; in liver disease, 547, 566, 584, 588, 591–2; with ulcerative colitis, 335, 344t, 347
- artificial sweeteners, 19, 225
- ASA, 148t, 150, 160, 165, 525t, 600, 612
- 5-ASA. *see* mesalamine
- Asacol®, 349–50
- ascariasis, 429t, 591
- ascites: about, 32–3, 612–13; and alcoholic liver disease, 570–1; causes, 47; chylous, 33; and cirrhosis, 592, 599–600, 601t; cirrhosis, 612–13; complications, 620–3; with congestive heart failure, 615; diagnosis, 613–15; dietary therapy, 63; examination for, 47–8; with hepatic encephalopathy, 624; infected, 33, 620; in liver disease, 32–3, 457, 501, 502t, 551, 570, 592, 599–600, 601t, 604, 606; management, 574, 616–20, 616–20; pancreatic, 438; pathogenesis, 612–20; and portal hypertension, 604, 606; in pregnancy, 653; refractory, 618; in veno-occlusive disease, 660
- ascitic fluid, 33
- ascorbic acid. *see* vitamin C
- aspartate aminotransferase, 197, 505, 513
- aspiration: children, 112; deglutition, 117; diagnostic, 33; and diverticula, 131; dysphagia, 97; enteral nutrition, 71–2; gastric, 172; with GERD, 107, 112, 693; and GI hemorrhage, 165; heartburn, 6; in neonates, 101; and squamous cell carcinoma, 128; vomited blood, 34
- aspirin. *see* ASA
- assimilation. *see* absorption; digestion
- asterixis, 599, 624
- asthma, 114
- ataxia, 23, 204t, 207
- ATG, 639
- atherosclerosis, 148t, 258, 264, 276, 279
- atonic colon, 386
- atresia: biliary, 64, 593, 730–1; duodenal, 689; esophageal, 101
- Auerbach's plexus, 90, 141, 176
- auscultation, 38, 42

- azathioprine, 314, 325t, 326, 352, 429t, 526, 567
- azithromycin, 295
- azotemia, 572, 627, 631
- azotorrhea, 424, 438, 442
- AZT, 291
- bacillary angiomatosis, 302
- Bacillus cereus*, 213–14, 712
- backwash ileitis, 337, 338f
- baclofen, 108
- bacterascites, monomicrobial nonneutrocytic, 621
- bacteremia, 75, 472
- bacteria: colonic, 195, 199, 362–4; causing diarrhea, 19, 202, 212–18, 213t, 233t; HIV-associated, 292, 293t
- bacterial infections, 292
- bacterial overgrowth syndrome, 57t, 193, 208, 226, 245t, 246–8, 321, 323
- bacteriocins, 245
- bacteroides, 244
- Bacteroides* species, 621
- balantidiasis, 341t
- Balantidium coli*, 320t, 392
- balloon angioplasty, 276
- Bantu siderosis, 55t
- barf. *see* vomiting
- barium x-ray, 7, 18, 97–8, 106t
- barley malt extract, 702t
- Barrett's ulcer, 95
- Barrett's epithelium, 105, 112, 127
- Barrett's esophagus, 98, 110, 112
- Barrett's metaplasia, 105, 108, 127
- basiliximab, 640
- basolateral membrane transport, 496f, 498–9
- beaver fever. *see* *Giardia lamblia*
- Behçet's syndrome, 114, 275t, 341t
- belching. *see* gas
- bentriomide test, 425–6
- benzathine penicillin, 408
- benzodiazepines, 523, 572, 625, 628
- beriberi, 57t
- Bernstein test, 98, 106t, 108
- beta adrenergic agent, 145
- beta blockers, 525t, 600, 609
- beta-adrenergic agonists, 609
- beta-glucuronidase, 465, 473
- beta-hydroxybutyrate dehydrogenase, 54
- betaine, 579
- betamethasone, 350
- Betnesol®, 350
- bezoars, 148t, 151, 173
- bicarbonate secretion, 157, 422, 712
- bifidobacteria, 244
- biguanides, 579
- bile: decreased output, 71; formation, 494–500; forming gallstones, 461; in gastritis, 146; in jaundice, 30; limy, 473; in urine, 31
- bile acids: bacterial overgrowth, 246–7; depletion, 60; causing diarrhea, 225, 226t, 230, 243, 479, 712; in digestion, 192–3; dissolve gallstones, 468; inflammatory bowel disease, 64t; malabsorption, 64t, 323, 456, 479, 712; micelles, 60
- bile duct: carcinoma, 316, 316t; congenital anomalies, 477; congenital diseases, 480–2; damage, 474; dilation, 31, 305; inflammatory diseases, 483–5; neoplasms, 479–80; obstruction. *see* cholestasis; roundworms in, 392; strictures, 465, 466t, 468t, 473, 479, 481, 483–5 *passim*; transport systems, 489–500
- bile gastritis, 151
- bile leaks, 485, 641
- bile salts: and bacteria, 245, 364; and cholelithiasis, 461–2; and Crohn's disease, 315t, 324; deconjugation, 193; and diarrhea, 226; in digestion, 245, 421, 494; dissolution, 468–9; enterohepatic circulation, 495f; gallstones, 462; inflammatory bowel disease, 64t; jaundice, 31; malabsorption, 193, 323–4, 364; and malassimilation, 201t; maldigestion, 23; replacement, 211t; vitamin K, 494; wastage, 231
- biliary atresia, 64, 482, 595, 730–1
- biliary cirrhosis, 64
- biliary colic, 25, 28, 467t, 470–1, 473–4
- biliary cysts, 481, 483
- biliary diversion, 735
- biliary dyskinesia, 478
- biliary sludge, 463, 478, 653
- biliary tract. *see* bile duct; gallbladder
- bilirubin: and bacteria, 245; children, 725; and choledocholithiasis, 474; and cholelithiasis, 465; and cirrhosis, 572, 591, 599, 601t; digestion, 245; in jaundice, 30–1, 726; and liver function, 505; and pancreatic carcinoma, 446; squamous cell carcinoma, esophageal, 129; tests, 505; total parenteral nutrition (TPN), 75
- bilirubin diglucuronide, 30, 501
- Billroth anastomoses, 146f, 151
- binding agents, 382t
- biofeedback training, 384
- biofilm, 473

- biologics, 80  
 biopsy, 98, 106t, 510–11  
 biotin deficiency, 57t  
 bisacodyl, 19, 702t  
 bisexuality, 297, 302–3  
 Bismuth classification, 486  
 bismuth compounds, 218  
 bisphosphonates, 148t, 151, 593  
 Bitot's spots, 203t, 205t  
 black liver, 529  
 Blastocystis hominis, 392  
 bleeding. *see also* blood loss; hemorrhage;  
 and alcoholic liver disease, 570;  
 choledocholithiasis, 475; and diarrhea, 20,  
 211, 216–17, 224; with diverticulitis, 373;  
 esophageal, 97, 113; GI tract, 33–5, 103,  
 408–13, 410t–11t, 413t, 606, 627; with  
 ischemia, 253; in liver disease, 504, 570–1,  
 600, 604–9 *passim*, 623, 626t; obscure, 34;  
 occult, 34; PUD, 157; rectal, 314, 315t,  
 318, 332–4, 342t, 365t, 380, 397–8, 403;  
 with tumors, 255; ulcer, 146f; vitamin K  
 deficiency, 205t, 206  
 blind loop syndrome, 201t, 226t, 244  
 bloating, 13–16, 60, 110, 218, 254, 297, 373,  
 377, 379, 382t, 438, 445. *see also*  
 distension  
 blood loss. *see also* bleeding; hemorrhage;  
 GI tract, 103, 318; and hookworms, 393;  
 inflammatory bowel disease, 64t; and  
 squamous cell carcinoma, 128  
 blood replacement, 607  
 blood in stool: about, 35–6; and ascites, 33;  
 children, 683, 713, 715; with colon cancer,  
 366; and constipation, 18, 386; with  
 diarrhea, 20, 211, 216–17, 231, 285, 390;  
 inflammatory bowel disease, 333; with  
 ulcerative colitis, 336  
 blood supply: anal canal, 395; esophagus, 89;  
 liver, 492; pancreas, 417, 418f; small  
 intestine, 175; stomach, 140–1  
 blood urea nitrogen, 34, 37  
 blood in vomit, 33, 36, 134, 165, 694t  
 blurred vision, 203t, 319, 348  
 body mass index, 66, 70  
 body piercing, 551, 551t  
 Boerhaave's syndrome, 134  
 bombesin. *see* gastrin releasing polypeptide  
 (GRP)  
 bone age, children, 704, 706t  
 bone deformities, 206  
 bone marrow depression, 327  
 bone metastases, 27  
 bones: aches, 204t; in celiac disease, 236;  
 deformity, 206; disease, 208, 482, 643; in  
 malassimilation, 204t, 206–8 *passim*; pain,  
 205t, 207; softening, 204t–5t; tenderness,  
 204t; vitamin deficiencies, 205t  
 borborygmi. *see* gas  
 botulinum toxin, 122  
 bougienage, 131, 133  
 bowel cleansing, 37  
 bowel habits, 18  
 bowel obstruction, 14, 25, 59, 70, 255, 323  
 bowel rest, 73, 77, 324, 373  
 bowel sounds, 44, 204, 279, 285, 335, 340  
 bradycardia, 375  
 bradykinin, 190t  
 brain tumor, 11, 117t  
 breast carcinoma, 126t, 648  
 breastfeeding, 703, 705, 729  
 breath hydrogen test, 60, 234, 238, 247, 321  
 bring up. *see* vomiting  
 bromocryptine, 628  
 bronchoscopy, 129  
 bronchospasm, 107, 694t  
 Brooke ileostomy, 353  
 brown bowel syndrome, 60t  
 bruising, 203t, 205t, 504  
 brush cytology, 98, 113, 129  
 Budd-Chiari syndrome, 583t, 598t, 602t,  
 615, 653, 659–60  
 budesonide, 326, 329, 350  
 bulbar poliomyelitis, 117t  
 burbulence. *see* gas  
 Burkitt's lymphoma, 303  
 burns, 115, 160, 477  
 burping. *see* gas  
 butyrate, 59  
 butyric acid, 199, 245  
  
 caffeine, 525t  
 cagA gene, 162  
 calcification: gallbladder, 472–3; pancreas,  
 27, 423–4, 435, 437  
 calcitonin, 226t  
 calcium: and Crohn's disease, 321;  
 deficiency, 204t, 235t; with fat  
 malassimilation, 206; inflammatory bowel  
 disease, 64t; malabsorption, 207;  
 supplements, 61–2, 210t, 592  
 calcium antagonists, 382t  
 calcium carbonate, 201t  
 calcium channel blockers, 17t, 109, 121–2,  
 124, 133, 231, 525t  
 calcium homeostasis, 207  
 calcium oxalate, 319  
 camera pill, 208

- Cameron's ulcers, 103  
 cAMP. *see* cyclic AMP  
 Campath-1H, 640  
 campylobacter, 20, 320t, 336  
 Campylobacter jejuni, 213t, 216, 292, 293t, 712  
 canalicular membrane transport, 498f, 499–500  
 cancer. *see* carcinoma; neoplasms  
 Candida, 113, 150, 399  
 Candida albicans, 6, 293t, 295–6  
 candidiasis, 133, 341t  
 caput medusae, 606–7  
 carbamazepine, 582  
 carbohydrates: absorption, 194–9, 227–8; anaerobic bacterial fermentation, 198f; and bacteria, 245; causing diarrhea, 227; digestion, 50, 51f, 227, 232, 385, 419; malabsorption, 226t, 228; malassimilation, 202–6, 235t; maldigestion, 244; malnutrition, 55–6; metabolism, 51f, 493; supplements, 71; tolerance test, 238; total parenteral nutrition (TPN), 74  
 carbon, 195  
 carbon dioxide, 245, 627  
 carbon tetrachloride, 524, 581  
 carbonated beverages, 134  
 carboxypeptidases, 199, 420  
 carcinoembryonic antigen, 366, 447  
 carcinoid, small intestine, 255  
 carcinoid syndrome, 21t, 231, 250, 649  
 carcinoma: adenoid cystic, 126t; adenosquamous, 126t; anal, 303; bile duct, 316t; cecum, 320t; cervical, 303; colonic, 343–5, 344t; colorectal, 303, 364–9, 398–9, 404, 648; causing diarrhea, 211; ductal, 481; esophageal, 115, 126t; gallbladder, 479–80; gastric, 11, 169f; giant cell, 444; hepatocellular, 557, 561, 572, 578, 583t, 585, 600, 627, 646–8; causing ischemia, 276t; medullary, 231; mucosal, 112; pancreatic, 439, 443–50; squamous cell, 125–8, 125t  
 carcinomatosis, 253  
 carcinosarcoma, esophageal, 7, 126t  
 cardiac arrhythmia, 253, 388  
 cardiac-caused cirrhosis, 598t  
 cardiogenic shock, 253, 275t  
 cardiomyopathy, cirrhotic, 610–11  
 cardiopulmonary bypass, 275t  
 cardiopulmonary resuscitation, 172  
 Caroli's disease, 480, 594  
 Caroli's syndrome, 481  
 carotene, 208, 321, 579  
 carotene deficiency, 238, 455  
 carotenemia, 31  
 casein, 71, 200  
 Castell's sign, 46  
 catecholamines, 49, 53, 63, 250, 263, 275t  
 catheter embolization, 75  
 catheterization, 75  
 caudal fibers, 88  
 CCK. *see* cholecystokinin (CCK)  
 cecum, 391  
 cefotaxime, 621  
 ceftriaxone, 293t, 389  
 celiac disease: about, 61–2, 520; in adults, 236; blood tests, 209; children, 235–6, 706t; complications and prognosis, 241; constipation, 236; diagnosis, 4; diet, 61–2, 241; and gastritis, 151; laboratory findings, 236–40; prognosis, 241; symptoms, 235t; treatment, 241  
 celiac plexus, 141  
 cell cycle: C0 phase, 749; G1 phase, 749, 751; G2 phase, 749; G2/M phase, 751; M phase, 749, 752; process, 748–50; regulatory mechanism, 752, 753f; S phase, 749, 751  
 Cellcept®, 639, 643  
 central nervous system, 117t, 206, 303, 586, 682  
 centroacinar cells, 418, 422  
 centromeres, 746  
 cephalosporins, 389–90, 621  
 cerebrotendinous xanthomatosis, 65t  
 cerebrovascular accident, 117t  
 ceroidosis, 60t  
 cestodes, 219  
 Chagas' disease, 122, 387  
 Charcot's triad, 474, 483  
 cheilosis, 23, 56, 203t, 205t, 207  
 chemical-induced esophagitis, 115–16  
 chemical-induced gastritis, 145–6  
 chemoreceptor trigger zone, 10, 11f  
 chemotherapy. *see* specific drugs  
 chenodeoxycholic acid, 245, 457, 468  
 chewing gum diarrhea, 227t  
 childbirth, 172, 382  
 Child-Pugh classification, 600–1, 605  
 children. *see also* infants; abdominal pain, 28–30, 236, 681–5; acalculous cholecystitis, 477; anemia, 684, 689, 693, 694t, 706t; aspiration, 112; biliary atresia, 730; bilirubin, 725; blood in stool, 683, 713, 715; bone age, 704, 706t; bone deformities, 206; calcium malabsorption, 207; celiac disease, 235–6, 706t;



- cholangitis, 465; cholestasis, 590; chronic abdomen, 28–30; cirrhosis, 593; constipation, 695–701, 702t; Crohn's disease, 324, 331; and cystic fibrosis, 453; cystic fibrosis, 453, 456–7, 718–25; diarrhea. *see* diarrhea, in children; edema, 721; enteritis, 688t, 711–12, 718; esophagitis, 114; failure to thrive, 720; fever, 690, 732; GERD, 112, 691–5; growth failure, 703–10; hepatitis, 531, 536; hepatobiliary disease, 722–5; Hirschsprung's disease, 387, 387–8; hypoalbuminemia, 721; hypothyroidism, 727; inflammatory bowel disease, 687t, 706t, 712; intestinal obstruction, 721; intussusception, 686; jaundice, 725–35; liver cancer, 648; liver disease, 689, 722; liver transplantation, 730; lung disease, 719; malnutrition, 701–10; Meckel's diverticulum, 249; meconium ileus, 719; megarectum, 387; pancreatic insufficiency, 718, 723–4; pancreatitis, 722; parasites, 393; portal vein thrombosis, 661; and protein deficiency, 206; pruritus, 732, 735; rectal prolapse, 721; rehydration therapy, 710–11, 714t; renal disease, 689; renal failure, 715; Salmonella, 389; Strongyloides stercoralis, 393; vitamin deficiency syndromes, 58t; vitamin D malabsorption, 207; volvulus, 689; vomiting, 684–5; Wilson's disease, 518, 585–6
- Child-Turcotte-Pugh score, 636
- Chlamydia, 292, 341t, 408
- chlordiazepoxide, 523t
- chloride: exchange, 187, 189; secretion, 189–90, 712
- chloridorrhea, 226t
- chloroform, 519t
- chlorpromazine, 523t, 582
- chlorpromamide, 582
- choking, 95
- cholangiocarcinoma, 465, 480, 485–7
- cholangiography, percutaneous transhepatic (PTC), 510
- cholangiopancreatography, endoscopic retrograde (ERCP), 40, 424, 435, 448–9, 474, 509–10
- cholangiopathy, 304–5
- cholangitis: about, 483; and cholecystitis, 472; and choledocholithiasis, 473–5; and cholelithiasis, 465–6; and cholestasis, 589–90; chronic, 465, 482; and ischemia, 253; nonsuperficial, 591; sclerosing, 64, 335–6, 344t, 346, 483–5, 593f, 594, 597, 598t
- cholecystectomy: acalculous cholecystitis, 478; and bile gastritis, 151; cholecystitis, 470; choledocholithiasis, 476–7; cholelithiasis, 460, 466, 469; for gallbladder carcinoma, 480; and gastric volvulus, 172; and HIV infection, 305
- cholecystitis: acalculous, 477–8; acute abdomen, 471–3; AIDS cholangiopathy, 305; and biliary colic, 467t; choledocholithiasis, 471–7; cholelithiasis, 465, 467; chronic acalculous, 478; chronic calculous, 470
- cholecystokinin (CCK), 56, 144–5, 192, 419, 421f, 478
- cholecystoses, 478–9
- choledochal cysts, 481, 594
- choledochojejunostomy, 482, 485
- choledocholithiasis, 466, 471–3
- cholelithiasis: about, 460; classification of, 460, 461t; clinical features, 465–7; complications, 466f; with Crohn's disease, 319; with cystic fibrosis, 456; diagnosis, 466; frequency of, 460, 461t; history, 465; inflammatory bowel disease, 316t; management, 467–9; causing pancreatitis, 430; in pregnancy, 653; risk factors, 464t; and short bowel syndrome, 243
- cholera, pancreatic, 231
- choleretic enteropathy, 19
- cholestasis: causes, 590t; and choledocholithiasis, 474; and cholelithiasis, 465; drug-induced, 584; enteral nutrition, 71; extrahepatic, 590–1; fat malabsorption, 193; causing hyperbilirubinemia, 32f; in infants, 481; inflammatory, 582–3; inherited, 732; intrahepatic, 589–90; jaundice, 28; malassimilation, 201t; management, 594–6; neonatal, 729–32; of pregnancy, 654–5; pure, 583
- cholestatic hepatobiliary disease, 23, 64
- cholestatic liver disease, 58t
- cholesterol: absorption, 53, 191f, 192–3; cholecystoses, 478; dietary therapy, 385; in digestion, 192; causing ischemia, 275t, 277f; malabsorption, 246; malassimilation, 209; role of liver, 494
- cholesterol embolus, 275t, 277f
- cholesterol esters, 53–4, 192
- cholesterol stones, 319, 460–1, 464t, 468, 473
- cholesterolosis, 478

- cholestyramine: to treat cholestasis, 655; and cirrhosis, 592; to treat Crohn's disease, 323; to treat diarrhea, 224, 231, 243; to treat fecal incontinence, 384; to treat irritable bowel syndrome, 382t; and malabsorption, 63, 64t; and malassimilation, 201t; causing malnutrition, 23; replacement, 211t
- cholic acid, 245, 247, 457, 463
- cholinergics, 213t
- chromatin, 745, 764–5
- chromatosomes, 745
- chromium, 56
- chromosomes: replication, 754, 758–9; structure, 745–7
- chronic abdomen, 28–30
- chronic fatigue syndrome, 592
- chronic mesenteric ischemia, 254
- Churg-Strauss syndrome, 151
- Chvostek's sign, 207
- chylomicrons, 53, 192–3
- chylous ascites, 33
- chymotrypsin, 56, 199, 420, 430
- cimetidine, 436, 442
- ciprofloxacin, 218t, 293t, 329, 353, 621, 623
- circulation. *see* blood supply
- circulatory collapse, 639
- cirrhosis: about, 596–8; alcoholic, 567, 571–2; and ascites, 47, 612–13; biliary, 64, 454, 457, 481, 521, 591–3, 597, 602t; causes, 598t; and cholelithiasis, 464t; and cholestasis, 589; clinical features, 598–600; complications, 504; cryptogenic, 578; dietary therapy, 63; drug-induced, 327, 584; and hepatitis, 557, 559t, 566–7; hepatocellular carcinoma, 561, 646; hepatorenal syndrome, 631; with inflammatory bowel disease, 316t; inherited, 585; and ischemia, 274; micronodular, 571, 597–8; pathology, 597; and portal hypertension, 602t; and PUD, 160; treatment, 600–1; with ulcerative colitis, 344t, 346
- cirrhotic habitus, 501, 502t
- cis-acting elements, 765–7, 769
- cisapride, 12, 108
- cisplatin, 171
- Citrobacter freundii*, 621t
- clarithromycin, 293t, 525t–6t
- clavulanic acid, 621
- clindamycin, 390
- clinical trials: design, 83–4; ethical concerns, 80, 85–6; informed consent, 85; institutional review committee, 86; investigators, 84; methodology, 82–3; monitoring, 85; phases, 81–2; planning, 83–4; reporting, 86
- clofazimine, 293t
- clofibrate, 464t
- Clostridium difficile*, 213t, 216, 224, 284, 336, 340, 341t, 390
- Clostridium perfringens*, 213–14, 712
- Clostridium species*, 244
- Clostridium welchii*, 149
- clotrimazole, 293t, 296
- clubbing, 502t, 504
- CMV. *see* cytomegalovirus
- coagulation disturbances, 504
- coagulopathy, 37, 502t, 601, 653
- cobalamin. *see* vitamin B12
- cobalt, 56
- cocaine, 148t, 151, 275t, 279, 519t, 584
- Coccidia, 222
- coccidioidosis, 296
- codeine, 323, 340, 525t
- coil embolotherapy, 612
- colchicine, 21t, 213t, 225, 233t, 573
- colectomy: for colon cancer, 368; GI bleeding, 412; for ulcerative colitis, 334, 345, 347, 352
- colestipol, 211t, 243
- colic: and acute abdomen, 24–5; biliary, 25, 28; children, 688t; and cholelithiasis, 465; renal, 29; ureteral, 25
- colipase, 192, 421
- colitis. *see also* ulcerative colitis; acute, 392; collagenous, 394; Crohn's, 282, 308, 319; causing diarrhea, 20, 216; dietary therapy, 62; diversion, 59, 362; eosinophilic, 394; and gastritis, 151; in graft-versus-host disease, 341t; and HIV, 292; ischemic, 35, 279–87, 280–7, 307, 321; lymphocytic, 394; microscopic, 394; postdysenteric, 222; pseudomembranous, 223–4, 320t
- collagen, 200
- collagen disease, 275t, 276, 645
- collagenous colitis, 151
- collagenous sprue, 201t, 241, 242f
- collateral circulation, 264
- collateral vessels, portosystemic, 604
- colon. *see also* colitis; abdominal mass, 39; about, 357; absorption and secretion, 360, 362–4; anatomy and function, 357–60; bleeding, 408–12; constipation, 384–8; digestion, 362–4; diverticulosis, 372–4; fecal incontinence, 381–4; infections, 388–92; irritable bowel syndrome, 377–81; motility, 361; neoplasms, 35t, 364–9,

- 364–72; nerve supply, 359f; obstruction, 374–7; perforation, 25
- colonic ileus, 375
- colonic mucosa, 59
- colonoscopy, 276t, 284, 336t
- colostomy, 59, 362
- coma, 63, 73, 172, 570, 624
- Compleat B®, 212t
- complete blood count (CBC), 26
- Condylomata acuminata, 303, 398–9, 407
- confusion, 253, 345t, 474
- congenital abnormalities, 101–3, 480–2
- congestive heart failure, 12, 35, 77, 205t, 253, 275t, 276, 279, 588, 615, 658–9
- conjunctival inflammation, 203t
- conjunctivitis, 316t
- connective tissue disease, 97, 394
- conococcal proctitis, 407
- constipation: about, 16–19, 695–6; with anal fissure, 405; causes, 385–6, 698t–9t; celiac disease, 236; children, 695–701, 702t; chronic, 17t; with colon cancer, 366; with cystic fibrosis, 455t, 456; defined, 384; diagnosis, 697–9; and diverticulitis, 373; with hepatic encephalopathy, 627–8; and Hirschsprung's disease, 700t; with irritable bowel syndrome, 377, 385; management, 699–701; in megarectum, 387; with neoplasms, 366, 450; with obstruction, 374, 385; pathophysiology, 696–7; in pelvic floor dyssynergia, 388; and proctitis, 212; with RAP, 684; treatment, 382t, 702t; and ulcerative colitis, 333
- constitutional growth delay, 704
- contraceptives: cholelithiasis, 464t; hepatic vein thrombosis, 659; hyperbilirubinemia, 529; ischemia, 275t, 280; liver disease, 579, 583; liver neoplasms, 580t, 583t, 584–5, 644
- convulsions, 57t
- copper, 56, 65t, 484, 586, 596, 600
- corneal changes, 58t, 203t, 205t
- Correa hypothesis, 149, 169
- Cortenema®, 350
- corticosteroids: to treat alcoholic liver disease, 572–3; to treat Chagas' disease, 77; to treat Crohn's disease, 325t, 326–7, 330; cytochromes, 525t; to treat gastritis, 152; to treat hepatitis, 567; and liver transplantation, 639; and nonalcoholic liver disease, 576; to treat pancreatitis, 436; role in digestion, 49; to treat sclerosing cholangitis, 484; to treat ulcerative colitis, 347–50,
- Cortifoam®, 350–1
- Cortiment®, 350
- costiveness. *see* constipation
- Cotazym®, 211t, 442
- co-trimoxazole, 218t
- coughing, 97, 107
- Cowdry's Type A, 113
- Coxsackie, 530
- cramps. *see* pain, abdominal
- creatinine, 27, 36, 616
- creatinine kinase, 265
- creatinine-height index (CHI), 66
- CREST syndrome, 591
- cricopharyngeus, 88
- Crigler-Najjar syndrome, 527–9, 528t, 727
- Crohn's disease, 73; abdominal pain, 28; about, 307; adenocarcinoma, 255; anatomic distribution, 308, 311t; bacterial overgrowth syndrome, 245t; children, 324, 331; chronic diarrhea, 21t; clinical features, 314–17; and colon cancer, 369; complications, 317–19; and constipation, 18; diagnosis, 320–2; and diarrhea, 226t; dietary therapy, 62–3; epidemiology, 309–11; and esophagitis, 114; etiology, 312–14; with fat malassimilation, 206; and fissures, 405; gastric, 148t, 151, 152t; incidence of, 312t; and ischemic colitis, 279, 284–5; manifestations of, 316t; nutrition, 76–7; pathology, 307–8; and small bowel, 243; and steatorrhea, 60; therapy, 208t, 323–31
- Cruveilhier-Baumgarten sign, 607
- crying. *see* children; colic
- cryoglobulinemia, 559
- cryotherapy, 648
- crypt abscess, 285, 331, 332f
- crypt hypoplasia, 59, 60t
- cryptococcosis, 20, 22, 296
- cryptosporidiosis, 221f
- Cryptosporidium: about, 222; causing diarrhea, 213t, 222, 298, 711; causing gastritis, 150; HIV-associated, 294t, 298, 305, 478
- Cullen's sign, 432
- Curling's ulcer, 160
- Cushing's disease, 520–1
- cutaneous changes, 502t, 504
- cyanocobalamin. *see* vitamin B12
- cyclamate, 246
- cyclic AMP, 19, 145, 187–90, 214, 230, 453
- cyclic GMP, 190, 215, 230
- cyclohexylamine, 246
- cyclo-oxygenases, 144, 150, 160–1

- cycloserine, 57t  
 cyclosporine: to treat Crohn's disease, 325t, 327, 348; in liver transplantation, 638–9; to treat ulcerative colitis, 352  
 cyproheptadine, 250  
 cystadenocarcinoma, 444  
 cystadenoma, 486  
 cystic fibrosis: about, 718; adult, 453–8; children, 453, 456–7, 718–25; and cholelithiasis, 464t; and cirrhosis, 590, 594; causing cirrhosis, 598t; complications, 454–7; diabetes, 455; diagnosis, 457; dietary therapy, 65t; gene therapy, 806–9; and growth failure, 706t; and malassimilation, 201t; management, 723–4; pancreatic insufficiency, 718–22; treatment, 458  
 cystinuria, 200, 201t  
 cysts: biliary, 481; congenital, 126t; with *Entamoeba histolytica*, 391; hepatic, 646; ovarian, 320t  
 cytochromes, 524–6  
 cytomegalovirus: causing acute hepatitis, 543; causing cholecystitis, 478; with Crohn's disease, 320t; causing gastritis, 147; causing hepatitis, 530, 543; HIV-associated, 294t, 295, 300; postoperative, 639; ulcerative colitis, 341t  
 cytoprotective agents, 606  
 cytosine, in gene sequences, 741  
 cytotoxic enterotoxins, 213  
 cytotoxic enterotoxins, 213  
 cytotoxin associated gene (*cagA*), 162
- Daclizumab, 640  
 danthron, 229t  
 dantrolene, 566  
 DDT, 444t, 445  
 debridement, 437  
 Declaration of Helsinki, 79, 86  
 defecation, 17–18, 29, 40, 377–9, 383f  
 deglutition, 90, 116–19  
 dehydration: assesesment and management, 714t; and constipation, 386; and diarrhea, 715; and enteral nutrition, 73; with hepatic encephalopathy, 627; with ischemia, 265; in pregnancy, 654; with toxic megacolon, 340, 345t; and vomiting, 10–11  
 delirium, 624  
 Delta agent. *see* hepatitis D  
 dementia, 57t, 204t, 624  
 demyelination of central nervous system, 206  
 Dent sleeve, 124f  
 deoxycholic acid, 65t, 245  
 deoxyribonucleic acid (DNA): and chromatin, 764–5; cis-acting elements, 765–7; gene sequences, 743, 745; methylation and transcription control, 781; mutations, 759–64; repair mechanisms, 761–4; replication, 753–9; structure, 741–2, 754t; transcription, 743, 764–81  
 depapillation of the tongue, 23  
 depression, 12, 30, 379  
 dermatitis, 57t, 203t, 205t, 235t, 399, 450  
 dermatitis herpetiformis, 201t, 236  
 dermatomyositis, 117t  
 dermatosis, scrotal, 203t  
 dextran, 618  
 dextrans, 195, 420  
 diabetes: and acute abdomen, 26; *Candida* esophagitis, 6; celiac disease, 235; and cholelithiasis, 464t; and constipation, 386; cystic fibrosis, 455; and diarrhea, 21t, 22, 192, 226t; and distension, 172; and dysmotility, 119; and electrolyte absorption, 192; and inherited liver disease, 588; ischemia, 275t, 276, 287; liver, 55t, 517, 551t, 559, 574–6 *passim*; and malassimilation, 201t; mellitus, 16, 113, 455; pancreas, 424, 426–7, 437, 444t, 445–6, 450–1; stomach, 172  
 diamine oxidase, 265  
 diaphoresis. *see* perspiration  
 diarrhea, acute: about, 209–12; bacterial, 212–18; causes, 209–11, 213t; children, 710–18; defined, 212; and diagnosis, 3; diagnosis, 22; invasive, 213; toxigenic, 213  
 diarrhea, in children: about, 710; assessment, 712–15; *Cryptosporidium*, 222; cystic fibrosis, 719; dietary therapy, 717; *Escherichia coli*, 217; management, 716–18; pathophysiology, 710–12; protein deficiency, 206; *Yersinia enterocolitica*, 216  
 diarrhea, choleraic, 323, 364  
 diarrhea, chronic: abnormal intestinal transit, 226, 228–30; anatomic approach to, 21t; bacterial, 212–18; causes, 225–6, 233t; and cystic fibrosis, 719; diagnosis, 22; exudative, 20, 231; with HIV, 302; investigating, 232; mechanisms, 226t; osmotic, 19, 226–8; secretory, 19–20, 229t, 230–1; self-induced, 231–2  
 diarrhea, in general: about, 19–22; and bacterial overgrowth syndrome, 247; and bile acid, 193, 243; bloody, 20, 211, 216–17, 285, 390, 393; and *C. difficile*, 390; carbohydrate malassimilation, 202,

- 204t; and carcinoid syndrome, 250; and celiac disease, 235t, 236; chewing gum diarrhea, 227t; with colitis, 394; with colon cancer, 366; with colonic obstruction, 374–5; and constipation, 18, 366; with Crohn's disease, 314, 315t, 323, 339, 342t; dietary therapy, 59–60; drug-related, 222–5, 350; and electrolyte absorption, 192; with eosinophilic colitis, 394; with fat malabsorption, 206; and growth failure, 706t; with HIV, 291–2, 297, 302; and hookworms, 393; inflammatory bowel disease, 64t; with ischemia, 254, 279, 285; and malabsorption, 209; and malnutrition, 59; nausea, 393; with pancreatic diseases, 438, 445; with Shigella, 388; short bowel syndrome, 243; with small bowel obstruction, 318; with *Strongyloides stercoralis*, 299; therapy for, 382t; with ulcerative colitis, 331, 333–4, 339, 342t; vitamin deficiency, 57t, 205t; in Whipple's disease, 251
- diarrhea, osmotic, 198f
- diarrhea, traveler's, 20, 218
- diazepam, 523t, 525t
- dicarboxylic acids, 60
- dichlorodiphenyltrichloroethane (DDT), 445
- diclofenac, 161, 582
- dicyclomine, 382t
- dideoxyinosine, 305
- diencephalic syndrome, 706t
- diet. *see also* alcohol; nutrition; alcoholic liver disease, 572, 574; anorexia, 12; carbohydrates, 194; cholelithiasis, 464t; constipation, 18; defined formula, 71; diarrhea, 59–60, 717; elemental, 71; enteral formulas, 71–2; “fad,” 64t; failure to thrive, 235, 703; fat intake, 192, 209; fiber, 382t, 384–5, 404–5; low-salt, 616; pancreatic cancer, 444t, 445; protein content, 199; restrictive, 64t; semi-elemental, 71; vitamin deficiency syndromes, 57t; vitamins and minerals, 178–83
- dietary therapy: anal fissures, 405; ascites, 63; celiac disease, 61–2; constipation, 701; diarrhea, 59–60, 717; diverticulosis, 372; fecal incontinence, 384; fiber, 382t; general principles, 59–63; GERD, 109; growth failure, 710; hereditary liver disease, 65t; inflammatory bowel disease, 62, 62–3, 324–5; ischemic disease, 286; lactose-free, 65, 323; liver disease, 63–5; low-fat, 324; malabsorption, 62, 64; malabsorption, 208t; pancreatitis, 441
- Dieulafoy lesions, 34, 165
- digestion: about, 178; carbohydrates, 50, 51f, 227, 232, 385, 419; colon, 362–4; fats, 50, 51f, 191f, 192–4; gallbladder, 192; protein, 50, 51f, 192, 199–202; stomach, 180; triglycerides, 53
- digitalis, 21t, 213t, 253, 275t, 287
- diglucuronide, 30
- dilation: to treat achalasia, 8, 122; to treat colitis, 287; colon, 221, 339–40, 345t; to treat esophageal stricture, 7; to treat esophagitis, 115; intrahepatic biliary, 31, 480; lymphatic, 307; peroral, 110–11, 127, 130, 133; to treat portal hypertension, 609; stomach, 172, 339
- diloxanide, 392
- diltiazem, 525t
- dioctyl sodium sulfosuccinate, 226t
- Dipentum®, 327, 349–50
- dipeptidylaminopeptidase IV, 200
- diphenylhydantoin, 523t
- diphenoxylate, 218t, 323, 348, 382t, 389
- diphyllobothrium latum, 57t
- direct tube tests, 424–5
- disaccharidase deficiencies, 201t, 226t, 227, 232–4, 315t
- disaccharidases, 59, 195, 197–9, 201
- disaccharides, 50, 196f, 197
- discharge, anorectal, 399
- disopyramide, 225
- disopyrobezoars, 173
- disorientation, 204t
- distal intestinal obstruction syndrome, 721–2
- distension. *see also* bloating; and acute abdomen, 25; after surgery, 172; and ascites, 33; with carbohydrate malabsorption, 204t; and celiac disease, 235–6; with colonic obstruction, 375; and constipation, 18, 386; and diarrhea, 230, 234; and diverticulitis, 373; and enteral nutrition, 72–3; by intraesophageal balloon, 99; with irritable bowel syndrome, 377; with ischemia, 253, 285; with liver disease, 33, 503, 571, 613; with toxic megacolon, 340; tracheoesophageal fistula, 101
- diuretics, 33, 253, 275t, 660; to treat alcoholic liver disease, 574; to treat ascites, 617; causing diarrhea, 232; causing pancreatitis, 429t
- divalent ions, 227
- diversion colitis, 59, 362

- diverticula. *see also* specific types; causing bacterial overgrowth, 245t; cricopharyngeal, 7; duodenal, 430t; esophageal, 131–3; gastric, 173; Meckel's, 249; pulsion, 133; small bowel, 201t, 245t; traction, 133
- diverticulitis, 26–7, 249–50, 286, 320t, 321, 373t, 376
- diverticulectomy, 131
- diverticulosis, 35t, 133, 372–4
- DNA. *see* deoxyribonucleic acid (DNA)
- doctor–patient relationship, 30, 290
- domperidone, 12, 382t
- dopamine, 190
- doxorubicin, 450
- doxycycline, 115, 218t
- drooling, 115
- drowsiness, 544
- drug abuse. *see* drugs
- drugs. *see also* clinical trials; and cholelithiasis, 464t; causing cholestasis, 582–3; and constipation, 17; causing diarrhea, 213t, 222–5, 232; and GI hemorrhage, 165; causing hepatitis, 517–18, 539; causing hyperamylasemia, 427t; illicit, 532, 599; causing liver disease, 579–85; and malabsorption, 64t; and malassimilation, 201t; metabolized by the liver, 522–6; and nutrient absorption, 63; overdose, 624, 627; pyridoxine-antagonists, 57t; causing vomiting, 11
- Dual Energy X-ray Absorptiometry (DEXA), 208
- Dubin-Johnson syndrome, 527, 528t, 529
- ductal cell adenocarcinoma, 444
- ductal cells, 418–19
- Dukes' classification, 365
- dumping syndrome, 21t, 233t
- duodenal atresia, 689
- duodenal ulcer disease: children, 160; cystic fibrosis, 454, 456; and gastric secretion, 155; and *H. pylori*, 155, 157, 162; pathophysiologic defects, 153t; treatment, 164; upper GI bleeding, 34t, 409
- duodenitis, 157
- duodenum: anatomy, 138–41; iron absorption, 182–3; physiology, 142–5; PUD, 155, 156f, 158f, 159–60
- Dupuytren's contracture, 502t, 571
- D-xylose, 59, 238
- dysentery, 218, 388
- dysfibrinogenemia, 502t, 504
- dysgammaglobulinemia syndromes, 241
- dysmotility, 119
- dyspepsia, 8–9, 16, 28, 145, 160, 350, 378. *see also* gas
- dysphagia: about, 6–7, 94–5; and achalasia, 94, 96, 122; classification of, 117t; colorectal, 343; diagnosis, 7; and diverticula, 131, 133; esophageal, 94–5, 105, 113, 116, 123; GERD, 107, 110, 694t; and HIV, 291, 295, 300–1; and iron deficiency, 207; malnutrition, 23; management, 7; oropharyngeal, 94–5, 116–19; and peristalsis mechanisms, 94; and squamous cell carcinoma, 128, 130; on treating portal hypertension, 608; and tumors, 125
- dysplasia, 112, 127, 169, 343, 345, 368
- dyspnea, 35, 207, 588
- dysproteinemia, 647
- dyssynergia, pelvic floor, 388
- eating, fear of, 274
- E. coli. see* *Escherichia coli*
- ecchymosis, 205t
- eclampsia, 652t, 654, 656–7
- ecstasy, 519t
- ectasia, vascular, 151
- eczema, 203t
- edema: bile duct, 439; with carbohydrate malassimilation, 204t; and celiac disease, 235t; cerebral, 624, 627; with cirrhotic ascites, 614, 618; with Crohn's disease, 307, 317; with hepatic encephalopathy, 624; and iron deficiency, 207; in liver disease, 33; in malassimilation, 206; malnutrition, 56, 77; and nutritional assessment, 69t; with pancreatic diseases, 438, 445; periportal, 346; with *Strongyloides stercoralis*, 299
- efavirenz, 291
- effusion, 33, 433t, 614, 637
- egg white: in enteral formulas, 71; excess ingestion, 57t
- elastase, 199
- elderly patients: achalasia, 58t, 122; acute abdomen, 26; chronic abdomen, 28; with cirrhotic ascites, 620; constipation, 386; dysphagia, 6; GI bleeding, 36; hepatitis, 532; ischemia, 253–4, 258, 272–3, 280, 284, 286; megarectum, 387; *Salmonella*, 389; ulcerative colitis, 339; vitamin deficiency syndromes, 122; volvulus, 172
- electrocoagulation, 402, 407
- electrolytes: abnormalities, 335; absorption, 185–92, 333; and acute abdomen, 27; disturbances, 73, 345t, 502t; enteral

- nutrition, 71; and gastritis, 148t;  
 inflammatory bowel disease, 64t; with  
 ischemic colitis, 285; secretion, 189–92;  
 total parenteral nutrition (TPN), 75  
 ELISA test, 391, 394, 539  
 embolectomy, 271–2  
 embolism, 243, 347  
 embolus, 271  
 emeprium bromide, 115  
 emphysema, 585  
 empyema, 472  
 encephalopathy: and alcoholic liver disease,  
 571–2; and cirrhosis, 592, 601t; with  
 cirrhotic ascites, 614; dietary therapy, 63,  
 63–5; hepatic, 245, 457, 502t, 623–9  
 encopresis, 387  
 endarterectomy, 276  
 endarteritis obliterans, 412  
 endocrine changes, 502t, 504  
 endocrine secretion, 77, 141  
 endometriosis, 29  
 endopeptidases, 199, 420  
 endoplasmic reticulum: protein processing,  
 795; protein targeting, 790–5; transport of  
 proteins, 795–9  
 endoscopy: abdominal mass, 40;  
 adenocarcinoma, 127; biliary tree  
 obstruction, 208t; caustic chemical  
 ingestion, 115; colitis, 413f; of colon,  
 362f; for colon cancer, 368; for Crohn's  
 disease, 321–2, 342t; dyspepsia, 9;  
 dysphagia, 7; esophageal disease, 98, 99f,  
 113–14, 119, 123, 125, 129, 133, 301; and  
 food-bolus obstruction, 134; foreign  
 bodies, 134; gastric, 145, 147, 151–3, 170;  
 GERD, 106t, 108, 110, 112; GI bleeding,  
 36–7, 165; hemostatic, 166; Mallory-Weiss  
 tear, 134; for pancreatic carcinoma, 448;  
 for ulcerative colitis, 336t, 337–9, 342t  
 endoysmium, 237  
 energy requirements, 69–70  
 enkephalins, 190, 192  
 Ensure®, 212t  
 Entamoeba histolytica, 213t, 221, 294t, 297,  
 336, 391–2, 712  
 enteral nutrition, 70–3, 76, 212t, 324, 349  
 enteritis: causing acute pancreatitis, 430t;  
 children, 688t, 711–12, 718; and  
 disaccharidase deficiencies, 233; and GI  
 bleeding, 35t; and HIV, 292; and  
 malassimilation, 201t; parasitic, 219–22  
 Enterobacter, 621t  
 enterocytes, 19, 60t  
 Enterocytozoon bienersi, 298  
 enteroenteric fistula, 245t  
 enteroogastrone, 144  
 enterohepatic circulation, 193  
 enterokinases, 199, 420, 421f  
 enteropathy: choleric, 19; in Crohn's  
 disease, 315t; gluten-sensitive. *see* celiac  
 disease; HIV-associated, 301–2; and  
 malnutrition, 23; nutritional intervention,  
 71; protein-losing, 23, 55, 64t, 68, 248–9,  
 302, 315t  
 enterotoxins, 188, 213–16, 226t, 230  
 Entocort®, 350  
 enzymes, 65t; liver, 722–3; pancreatic, 60,  
 419–21, 442; to treat pancreatic  
 insufficiency, 724; replacement, 457–8; role  
 in metabolism, 524–6; secretion of,  
 419–21; supplements, 208t  
 eosinophilic colitis, 394  
 eosinophilic esophagitis, 114  
 eosinophilic gastritis, 152  
 eosinophilic gastroenteritis, 341t  
 eosinophilic pneumonitis, 392  
 epidermoid carcinoma, 126t, 444  
 epidermolysis bullosa, 114  
 epiphrenic diverticula, 133  
 epirubicin, 171  
 episcleritis, 316t, 319, 345t, 348  
 Epsom salts, 227t  
 Epstein-Barr virus, 429t, 530, 543, 642  
 ERCP. *see* cholangiopancreatography,  
 endoscopic retrograde (ERCP)  
 ergocalciferol. *see* vitamin D2  
 eructio nervosa, 15  
 erythema nodosum, 316t, 319, 335, 345t,  
 347–8  
 erythro, 526t  
 erythrocyte sedimentation, 321, 333, 335  
 erythrocytosis, 647  
 erythromycin, 216, 293t, 525t, 582  
 Escherichia coli: about, 214–15; causing  
 cholecystitis, 476; causing diarrhea, 19–20,  
 213t, 217–18, 226t, 230, 712; causing  
 peritonitis, 621, 621t; in small intestine,  
 244; types, 215t; and ulcerative colitis,  
 336, 341t  
 esophageal spasm, 6–8, 118f, 119, 121  
 esophageal sphincter, lower: anatomy, 88–90;  
 function, 94; GERD, 103; motor disorders,  
 6–7, 108; vomiting, 90  
 esophageal sphincter, upper: anatomy, 88–90;  
 function, 91  
 esophageal transection, 608  
 esophageal ulceration, 72  
 esophagitis: allergic, 114; chemical-induced,

- 114; eosinophilic, 114; and food-bolus obstruction, 134; GERD, 105, 108, 693; causing hemorrhage, 165; immune-mediated, 114–15; infectious, 34, 113–14; nonreflux-induced, 113–16; peptic, 34; pill, 34; and vomiting, 11
- esophagus: about, 88; anatomic variants, 101–5; anatomy, 88–90; angina-like pain, 123–5; blood supply, 89; diagnostic investigations, 97–100; diseases, 94–7; histology, 89–90; hypertensive peristalsis, 118f; innervation, 89; irritable, 125; lymphatic drainage, 89; motor disorders, 6–7; nutcracker, 118f, 119, 121; physiology, 90–4; primary disorders, 119; rings, 130–1; secondary disorders, 119; ulcers, 155; webs, 130–1
- estrogens, 275t, 287, 429t, 464t, 525t, 651
- etanercept, 347
- ethambutol, 293t
- ethanol: causing diarrhea, 226t, 227; liver disease, 504, 512, 569, 647
- ethanolamine, 608
- ethics, 232, 574
- ethnicity: and celiac disease, 236; choledochal cysts, 481; and cholelithiasis, 464t; and cholestasis of pregnancy, 654; and Crohn's disease, 311; and cystic fibrosis, 453; and enzymatic metabolism, 525; and lactase deficiency, 199, 227, 233–4, 684; and lactose intolerance, 379; and lymphoma, 255; and osmotic diarrhea, 227. *see also* geographic factors; sclerosing cholangitis, 483; and squamous cell carcinoma, 128
- etodolac, 161
- eukaryotic cells: cell cycle, 748–50; cellular compartmentalization, 789–806; classes of RNA, 739, 741; expression of genetic information, 771; flow of genetic information, 747–8; post-transcription processing, 772–80; post-translational processing, 787–806; transcription, 764–72
- eukaryotic genomes: molecular anatomy, 743–4; organization, 744–7; regulation, 772–80
- Everolimus®, 640
- excess egg white ingestion, 57t
- exercise, 5–6, 520, 610
- exocrine cells, 56
- exons: defined, 743; splicing, 776, 777f, 781f
- exopeptidases, 199
- eye problems, 203t, 205t, 316t, 319, 345t, 348
- Fabry's disease, 320t
- factor II, 494, 504
- factor IX, 494, 504
- factor V, 347, 494, 504
- factor VII, 494, 504
- factor VIII, 347
- factor X, 494, 504
- failure to thrive. *see also* growth failure; about, 703; assessment, 705–9; cystic fibrosis, 720; GERD, 693, 694t
- famciclovir, 294t, 301
- Familial Adenomatous Polyposis (FAP) Syndrome, 173, 368
- familial polyposis syndrome, 173, 364, 368
- familial short stature, 704
- famotidine, 442
- farting. *see* gas
- fasting, 20, 46, 55t, 63, 225, 318, 437, 450, 527, 528t, 529
- fat. *see also* triglycerides; absorption, 192–4; dietary intake, 209; in digestion, 50, 51f, 192–4; malabsorption, 193, 198, 243, 246, 315t, 319, 724; malassimilation, 206, 235t; metabolism, 50, 51t, 493–4; in stool. *see* steatorrhea; total parenteral nutrition (TPN), 74
- fatigue: and alcoholic liver disease, 570; and celiac disease, 236; and gastritis, 147; and GI bleeding, 35; and hepatitis, 566; and inherited liver disease, 588; and iron deficiency, 207; in liver disease, 501; with pancreatic diseases, 445; with ulcerative colitis, 334
- fatty acids. *see also* prostaglandins; deficiency, 455; and diarrhea, 19, 225, 226t, 227, 230, 324; in digestion, 49–50, 143, 192–3; enteral formulas, 71; hydroxylated, 188; linoleic acid, 74; lipolysis of, 50; long-chain, 206, 324, 364; luminal, 59; malassimilation, 206; malnutrition, 59; oxidation, 54; reabsorption, 199; short-chain, 195, 197, 228, 245, 324
- fatty liver: about, 517; alcoholic liver disease, 569; causing cirrhosis, 598t; causing hepatitis, 551t; and malnutrition, 23, 56; nonalcoholic liver disease, 574–9; in pregnancy, 655–6; with ulcerative colitis, 346
- fear of eating, 274
- fecal impaction, 276t
- fecal incontinence, 398
- fecal occult blood test, 34
- fedotazine, 382t



- feeding center, 12  
 ferritin, 208, 577  
 Festal®, 211t  
 fetor hepaticus, 624  
 fever: and alcoholic liver disease, 570; and biliary colic, 467t; Boerhaave's syndrome, 134; children, 690, 732; cholecystitis, 305, 471–2; with cirrhotic ascites, 614; with Crohn's disease, 314, 342t; diagnosis, 4; and diarrhea, 215–19, 224; with diverticulitis, 375; and gastritis, 147; and HIV, 292, 296, 303; inflammatory bowel disease, 64t; with irritable bowel syndrome, 380; with ischemic colitis, 285; in liver disease, 501, 502t; with liver transplantation, 641; and pancreatitis, 432; with *Shigella*, 388; with *Strongyloides stercoralis*, 299; with toxic megacolon, 340, 345t; and ulcerative colitis, 333–4, 342t, 346; in Whipple's disease, 251  
 fiber, 18, 59, 73, 195, 382t, 384–5, 404–5  
 fibrinogen, 347, 494  
 fibrinolytic agents, 287  
 fibroma, small intestine, 255  
 fibrosis. *see also* cystic fibrosis; and cirrhosis, 596; congenital hepatic, 602t; drug-induced, 584; esophageal, 107; idiopathic portal, 602t; liver, 346, 481, 548t, 571; pancreas, 437, 439; retroperitoneal, 194; submucosal, 151; of varix lumen, 608  
 Filaria species, 394  
 fissures, anal: about, 404; and bleeding, 413t; carcinoma, 303; with Crohn's disease, 318; diagnosis, 405; and HIV, 292; with inflammatory bowel disease, 316t; causing pain, 396–7; pathogenesis, 405; with perianal mass, 398; and proctalgia fugax, 40; treatment, 405–6; with ulcerative colitis, 344t  
 fissures, mouth, 203t, 207  
 fistula-abscess disease, 406  
 fistulas: anal, 128, 130, 303, 344t, 399; aorto-enteric, 34; aortoenteric, 410t; with cholecystitis, 472; colcutaneous, 373t; colonic, 391; colovaginal, 373t; colovesical, 373t; with Crohn's disease, 342t; causing diarrhea, 226t; enteroenteric, 245t, 318; esophagorespiratory, 128, 130; gastrocolic, 245t; perianal, 318; perirectal, 318; rectovaginal, 316t, 344t; rectovesical, 316t; small bowel, 201t, 308, 310f; splenic, 602t; tracheoesophageal, 101–3; with ulcerative colitis, 342t  
 fistulotomy, 406  
 FK-506, 639  
 Flagyl®, 390  
 flatulence. *see* gas  
 flatus. *see* gas  
 flatworms, 219  
 Fleete®, 401  
 flora: colon, 349; fecal, 227; and gas, 14; small intestine, 244–6  
 floxuridine, 584  
 fluconazole, 113, 293t, 296, 526t  
 fluid thrill, 33  
 flukes, 219, 465  
 flumazenil, 628  
 fluoroquinolones, 389, 526t  
 fluoroscopy, 116  
 5-fluorouracil, 171  
 fluoxetine, 526t  
 flushing, 250  
 fluticasone, 114  
 fluvoxamine, 526t  
 flux. *see* diarrhea  
 focal nodular hyperplasia, 644–5  
 focal segmental ischemia, 279  
 folacins, 178  
 folate deficiency, 23, 62, 179, 203–5t, 206, 208, 235t, 236–7, 246  
 folic acid: absorption, 178–9; deficiency, 57t, 59, 60t, 64t, 207, 321; digestion, 245; replacement, 210t  
 follicular hyperkeratosis, 203t, 206, 235t  
 food. *see* diet; nutrition  
 Food and Drug Administration, 81  
 food poisoning, 213–14  
 foreign bodies: esophagus, 134; stomach, 148t, 151  
 formic acid, 199  
 Formula 2®, 212t  
 foscarnet, 294t, 300–1  
 fractures, 207  
 fructose, 65t, 197, 227t  
 fructose intolerance, 706t  
 fundoplication, 109, 695  
 fungal infection, 295–7  
 fungemia, 75  
 furosemide, 429t, 617–18  
 GABA<sub>B</sub> receptors, 108  
 galactosemia, 65t, 597, 598t, 706t  
 gallbladder: abdominal mass, 39; and cystic fibrosis, 456; in digestion, 192; and HIV, 304; inflamed. *see* cholecystitis; and jaundice, 31; neoplasms, 479–80; with pancreatic diseases, 445; ulcers, 155

- gallbladder disease: acalculous cholecystitis, 477–8; cholecystoses, 478–9; congenital, 477; neoplasms, 479–80; postcholecystectomy, 479
- gallstones. *see* cholelithiasis
- gamma-glutamyl transpeptidase, 506, 517
- ganciclovir, 294t, 300
- Gardner's syndrome, 368
- gas. *see also* dyspepsia; about, 13–16; with celiac disease, 235t, 236; in cholelithiasis, 454; with GERD, 110; irritable bowel syndrome, 378; with malabsorption, 227; with malassimilation, 202–4; with ulcerative colitis, 335
- gaseous distension. *see* gas
- gastrectomy, 151, 171
- gastric acid secretion: in disease, 155, 163, 168, 389, 451; mechanism, 143–4
- gastric atrophy, 57t
- gastric cystica profunda, 152t
- gastric erosions, 34t
- gastric folds, 142, 149, 152
- gastric lymphoma, 171
- gastric phycomycosis, 150
- gastric rupture, 172
- gastric secretion: gastric acid, 143–4; intrinsic factor, 141, 143, 150; mucus, 141; pepsinogen, 141, 144
- gastric ulcer disease, 154f
- gastric varices, 152t
- gastric volvulus, 172
- gastrin: causing diarrhea, 226; and protein absorption, 199; role in digestion, 199; secretion, 144, 163, 423; in Zollinger-Ellison syndrome, 231
- gastrin releasing polypeptide (GRP), 190t
- gastrinoma, 144t, 450–1
- gastritides, 147–53, 148t
- gastritis: about, 145–6; atrophic, 153; autoimmune, 150; bacterial, 147–50; bile-reflux, 151; chemical-induced, 145–6; classification of, 148t; collagenous colitis, 151; and dysplasia, 169; eosinophilic, 152; fungal, 150; and gastric cancer, 169, 169–70; gastritides, 147–53; granulomatous, 151; parasitic, 150; and portal hypertension, 606t; viral, 147
- gastritis cystica profunda, 148t, 153
- gastrocolic fistula, 14, 245t
- gastroduodenitis, erosive, 160, 165
- gastroenteritis: bacterial, 214–17; causing diarrhea, 214–17, 219; eosinophilic, 320t; and malabsorption, 198; viral, 219
- gastroenterostomy, 244
- gastroesophageal reflux disease (GERD). *see* GERD
- Gastrografin®, 134, 456
- gastroparesis, 12
- gastropathy: chemical, 146, 148t, 150; hypertrophic, 152; portal hypertensive, 606–7
- gastrostomy, percutaneous endoscopic, 71
- “gay bowel syndrome,” 22
- G-cell hyperplasia, 160, 450
- gemcitabine, 171, 449
- gender. *see* sex
- gene sequences. *see also* transcription; DNA, 743, 745; mRNA, 743; size, 744
- gene therapy, cystic fibrosis, 806–9
- genes: expression. *see* transcription; translation; families, 524; mutation, 525
- gentamycin, 476
- geographical factors. *see also* ethnicity; cholestasis of pregnancy, 654; diarrhea, 20; gallstone disease, 460; hepatitis B, 553; lactase deficiency, 199, 227; parasites, 299, 591; squamous cell carcinoma, 128
- GERD (gastroesophageal reflux disease): about, 105, 691; chest pain, 124; children, 691–5; clinical features, 8, 107; complications, 110–12, 693–4; cricopharyngeal myotomy, 118, 131–2; and cystic fibrosis, 455t; diagnosis, 106t, 107–8, 692–5; and esophageal disorders, 97; and esophageal motor disorders, 119, 123; and growth failure, 706t; heartburn, 95; and Heller myotomy, 122; and hiatus hernia, 101f, 103, 105; management, 695; pathophysiology, 105–7, 691–2; and pneumatic balloon dilation, 122; schematic representation, 104f; treatment, 108–10; and vomiting, 11
- giant cell carcinoma, 444
- giant hypertrophic gastritis. *see* Ménétrier's disease
- Giardia lamblia: about, 219–20; causing diarrhea, 21t, 213t, 718; and HIV, 297; treatment, 294t
- giardiasis, 22, 219–20, 321
- Gilbert's syndrome, 32f, 503, 505, 527, 528t, 727
- gliadin, 234, 237
- globulins, 507, 533, 538
- globus, 4–5
- glomerular filtration rate (GFR), 68
- glomerulonephritis, 554, 559, 591
- glossitis, 57t; with carbohydrate malassimilation, 203t; and celiac disease,

- 235t; in malnutrition, 23, 56; vitamin B12 deficiency, 207; vitamin B6 deficiency, 205t
- glucagon: to treat alcoholic liver disease, 573; with carbohydrate malassimilation, 204; depletion, 63; and food-bolus obstruction, 134; in glucagonomas, 231; and pancreas, 423; role in digestion, 49, 53
- glucagonoma, 450
- glucoamylase, 195
- glucocorticoids, 160, 190, 394
- gluconeogenesis, 53–4, 63–4, 494
- glucose: absorption, 185–6, 194f, 197; digestion, 49–50; malnutrition, 55–6, 59, 77; total parenteral nutrition (TPN), 74
- glucose galactose, 227t
- glucose oligosaccharides, 71
- glucose-saline replacement therapy, 231
- glucuronide, 30
- glutamine, 53
- gluten, 200, 208t
- gluten-sensitive enteropathy, 61, 234–42. *see also* celiac disease
- glycerin, 702t
- glycine, 245, 457
- glycogen, 50, 54, 63, 194
- glycogen acanthosis, 126t
- glycogen storage disease, 65t, 706t
- glycogenolysis, 50, 53
- glycolysis, 50t, 189
- glycoproteins, 180, 197, 420
- goiter, 203t
- gold, 341t
- Golgi apparatus, 197, 201, 420, 801–3
- GoLYTELY™, 722
- gonococcus, 22
- gonorrhea, 292, 341t, 407
- Good Clinical Practice (GCP), 79
- graft dysfunction, 641
- graft-versus-host disease, 131, 146, 148t, 150, 341t, 602t
- granular cell tumor, esophageal, 126t, 127
- granuloma, 307
- granulomatosis, allergic, 275t
- granulomatous gastritis, 148t, 151
- granulomatous inflammation, liver, 583
- Grey Turner's sign, 432
- group D streptococci, 621t
- growth failure. *see also* failure to thrive; about, 703; assessment, 705–9; constitutional growth delay, 704; diagnosis, 706t; dietary therapy, 710; enteral nutrition, 77; familial short stature, 704; management, 710; small for gestational age, 704
- growth hormone, 53
- GRP. *see* gastrin releasing polypeptide (GRP)
- guanethidine, 213t
- guanine, in gene sequences, 741
- guanylate cyclase, 215, 230
- guarding of abdominal muscles, 25–6
- Guillain-Barré syndrome, 547
- gum disease, 58t, 203t, 205t
- gums (dietary fiber), 195
- gut hypersensitivity, 15
- gut transit study, 18
- gynecomastia, 502t
- H+/K+-ATPase, 36, 143, 150
- H+/K+-ATPase pump. *see* proton pump
- H. pylori. *see* Helicobacter pylori
- H2 antagonists. *see* H2-receptor antagonists
- H2 blockers. *see* H2-receptor antagonists
- H2-receptor antagonists: to treat cystic fibrosis, 458; to treat dyspepsia, 9; to treat gastritis, 152; to treat Meckel's diverticulum, 250; to treat pancreatitis, 442
- HAART, 291, 302, 304, 306
- hair problems, 203t, 205t
- halothane, 582
- hamartoma, small intestine, 255
- Harris-Benedict equation, 69–70, 76
- Hartnup's disease, 200, 201t
- Hashimoto's thyroiditis, 150
- head circumference, children, 705–7
- headache, 216, 250, 319
- heart disease, 96, 108, 250, 253, 284, 732
- heart failure, 47, 57t, 205t
- heartburn: about, 5–6; achalasia, 122; and esophageal disorders, 95; and esophageal motor disorders, 119; GERD, 95; with irritable bowel syndrome, 378; in scleroderma esophagus, 122–3
- height, children, 705–7
- Helicobacter pylori: appearance of, 139f; and dyspepsia, 8; and gastric cancer, 168–71; and gastric folds, 152t; and gastritis, 146f, 148t, 149, 151, 169; isolation of, 138; and NSAIDs, 161; and pseudolymphoma, 173; and PUD, 155–9, 162–4
- helix-loop-helix, 769
- Heller myotomy, 122
- HELLP syndrome, 657
- hemacel, 618
- hemagglutination test, 221, 391
- hemangioma: cavernous, 645–6; esophagus, 126t
- hematemesis. *see* blood in vomit

- hematochezia, 398. *see also* blood in stool
- hematoma, perianal, 403
- hematuria, 474
- hemobilia, 34, 410t
- hemochromatosis: and cirrhosis, 571, 597; dietary therapy, 65t; genetic, 518; in inherited liver disease, 586–9
- hemolysis, 31, 32f, 204t, 505
- hemophilia, 290
- hemorrhage. *see also* bleeding; blood loss; with amebiasis, 221; colonic, 344t, 347; and diagnosis, 3; with GERD, 112; with inflammatory bowel disease, 316t; and ischemia, 275t, 276; and ischemic colitis, 285; and malnutrition, 58t; mucosal, 151; and NSAIDs, 160; postpartum, 653; and PUD, 165; treatment, 166–7; upper GI, 161, 164–8
- hemorrhoidectomy, 404
- hemorrhoids, 35t, 40, 344t, 396–9, 402–4, 412, 413t
- hemosiderin, 285
- hemostasis, 134, 166
- hemosuccus pancreaticus, 34
- heparin, 272, 660
- hepatectomy, 480–1
- hepatitis A, 292, 517, 531–5
- hepatitis, acute: about, 530–1, 582; causes, 530t; complications, 544–7; figures, 543f, 545–6f; pathology, 544; types, 531–43
- hepatitis, alcoholic, 566t, 567, 602t, 603
- hepatitis, autoimmune, 518, 566–7, 590, 597, 598t
- hepatitis B: about, 517, 536–8; acute, 536–8; causes, 551t; chronic, 517, 552–9; and cirrhosis, 571, 598t; diagnosis, 552t; drug-induced, 327; and hepatocellular carcinoma, 646; and HIV, 292, 304; in pregnancy, 653; prevention and treatment, 534t; risk, 535t
- hepatitis C: about, 515, 539–40; and alcoholic liver disease, 568, 571; causes, 551t; chronic, 515, 559–65; and cirrhosis, 598t; and HIV, 304; in pregnancy, 653; prevention and treatment, 534t; risk, 535t
- hepatitis, chronic, 602t; about, 548–51; and cirrhosis, 597; diagnosis, 544; drug-induced, 584; with inflammatory bowel disease, 316t; risk factors, 551t; types, 552–65; with ulcerative colitis, 346; viral, 550–65
- hepatitis D: about, 540–1, 565; and cirrhosis, 598t
- hepatitis, drug-induced, 517–18, 519t, 551t, 566
- hepatitis E, 541–2
- hepatitis G, 543
- hepatitis GB, 543
- hepatitis, ischemic, 506, 658
- hepatitis, neonatal, 536
- hepatitis serology, 507
- hepatitis, viral, 32, 429t, 530–65, 547t, 566t, 597, 598t. *see also* specific types
- hepatobiliary disease, children, 722–5
- hepatobiliary function, 493–500
- hepatoblastoma, 648
- hepatocellular adenoma, 644
- hepatocellular carcinoma, 557, 561, 572, 578, 583t, 585, 600, 627, 646–8
- hepatocellular disease: clinical features, 346; and jaundice, 31; malassimilation, 201t; reduces coagulation factors, 494
- hepatocellular dysfunction, 32f
- hepatocellular injury, 581–2
- hepatocytes, 30, 492, 596
- hepatomegaly: and alcoholic liver disease, 570–1; with carbohydrate malassimilation, 204t; Caroli's disease, 480; and esophageal disorders, 97; in esophageal disorders, 128; and HIV infections, 303; and jaundice, 31; in liver disease, 503–4; and malnutrition, 23; in pregnancy, 653
- hepatopulmonary syndrome, 611–12
- hepatorenal syndrome, 571, 629–32
- hepatosplenomegaly, 292, 567, 595, 723
- hepatosteatonecrosis. *see* fatty liver
- herbal remedies, 519t, 584
- heredity: gastric cancer, 171; colon cancer, 369; cystic fibrosis, 453; disaccharidase deficiencies, 232, 234; fructose intolerance, 65t; liver disease, 56t, 65t, 585–9; pancreatitis, 437, 444; PUD, 159–60
- hernia, 376
- herpes: causing acute hepatitis, 530; causing esophagitis, 6, 113–14; causing gastritis, 147; causing hepatitis, 652; HIV infections, 294t, 295, 301; inflammatory bowel disease, 341t; sexually transmitted disease (STD), 408
- herpetic mouth, 113
- heterogenous nuclear RNA, role, 743
- heterosexuality, 290, 535t
- heterotopia, esophageal, 126t
- hiatus hernia, 101f–2f, 103–5, 172
- High-Nitrogen Vivonex®, 212t
- hilum, 140
- Hippel-Lindau disease, 450
- Hirschsprung's disease, 358, 387, 698, 700t

- histamines, 109, 145, 167, 190t, 250  
 histones, 745  
 Histoplasma, 150  
 histoplasmosis, 293t, 296, 320t, 341t  
 history-taking, 3–4  
 HIV: about, 289; causing acute pancreatitis, 429t; basic principles, 289–91; and cholestasis, 590; GI involvement, 291–303; hepatitis, 535t; treatment, 291, 293t–4t  
 HIV enteropathy, 302  
 HIV wasting syndrome, 305–6  
 hnRNA. *see* heterogenous nuclear RNA  
 hoarseness, 97, 107, 128  
 Hodgkin's disease, 303  
 homosexuality: and cytomegalovirus, 300; and diarrhea, 22; Giardia lamblia, 297; hepatitis, 535t; and HIV, 290; Kaposi's sarcoma, 302; and sexually transmitted diseases, 407; squamous cell carcinoma, 303  
 hookworms, 393  
 hormones. *see also* specific types; affecting electrolyte absorption, 188; causing diarrhea, 19, 228, 712; gastrointestinal, 144; and intestinal secretion, 190, 230–1; causing liver neoplasms, 647; role in digestion, 50–3, 188  
 Human Genome Project, 738  
 human genomes. *see* eukaryotic genomes  
 human immunodeficiency virus. *see* HIV  
 human papilloma virus, 303  
 hunger, 12, 682  
 hydrocephalus, 11  
 hydrochloric acid: and gas, 13; secretion of, 141, 143  
 hydrocortisone acetate, 350  
 hydrogen, 201–2, 245  
 hydrogen sulfide, 245  
 hydrops, gallbladder, 473  
 hydroureter, 27  
 3-hydroxybutyrate dehydrogenase, 54  
 hydroxylases, 524  
 hyoscyamine, 382t  
 hyperaldosteronism, 617  
 hyperalimentation, 437  
 hyperammonemia, 64  
 hyperamylasemia, 265, 427–8, 434  
 hyperbilirubinemia: alcoholic liver disease, 571; causes, 32f; cholecystitis, 471; congenital, 527–30; conjugated, 529–30, 729–32; jaundice, 31, 501–3; management, 729; measuring, 505; neonatal hepatitis, 722; unconjugated, 527–9, 726–9  
 hypercalcemia, 16, 385–6, 429t, 431, 647  
 hypercholesterolemia, 576  
 hypercoagulability, 274  
 hyperdynamic circulation, 502t, 504  
 hyperemesis gravidarum, 76, 654  
 hypergammaglobulinemia, 540, 567  
 hypergastrinemia, 144, 450  
 hyperglycemia, 73, 75  
 hyperimmune bovine colostrum, 222  
 hyperkalemia, 73  
 hyperkeratosis, 58t, 205t  
 hyperlipidemia, 74, 431, 516t  
 hyperlipoproteinemia, 429t, 431  
 hyperosmolar nonketotic coma, 73  
 hyperoxaluria, 243, 319  
 hyperparathyroidism, 144t, 431  
 hyperpepsinogenemia, 160  
 hyperperistalsis, 35, 386  
 hyperphosphatemia, 73  
 hyperplasia: benign lymphoid, 320t; bowel, 237, 307; in Crohn's disease, 307; focal nodular, 644–5; foveolar, 150, 152–3; gallbladder, 479; G-cell, 144t, 451; nodular regenerative, 645; causing portal hypertension, 602t; stomach, 173  
 hyperreflexia, 624  
 hypersalivation, 9  
 hypersecretion, 144t, 148t, 152, 450  
 hypersensitivity pneumonitis, 327  
 hypersomnia, 624  
 hypersplenism, 457, 504  
 hypertension, 33–4, 151, 576  
 hyperthyroidism, 20, 21t, 144t, 226, 226t, 706t  
 hypertriglyceridemia, 75, 576  
 hypertrophic pyloric stenosis, 172  
 hyperuricosuria, 458  
 hypoalbuminemia, 23, 56, 333–5, 340, 345t, 721  
 hypocalcemia, 16, 58t, 207, 335  
 hypochlorhydria, 152, 169, 451  
 hypochondriasis, 30  
 hypochromia, 37  
 hypogammaglobulinemia, 201t, 222, 249  
 hypoguesia, 203t, 205t  
 hypoglycemia, 494, 570, 573, 627, 647  
 hypokalemia, 73, 75, 335, 343, 365t, 366, 451, 617, 627  
 hypomagnesemia, 73, 207, 335  
 hyponatremia, 73, 627  
 hypoparathyroidism, 21t  
 hypoperfusion, 260, 275–6  
 hypophosphatemia, 73, 75  
 hypoproteinemia, 235t, 249, 694t  
 hypoprothrombinemia, 235t, 502t

- hyporeflexia, 204t  
 hypospemia, 350  
 hypotension, 26, 36, 224, 253, 276, 279, 345t, 430, 474, 570, 614  
 hypothalamus, 12  
 hypothyroidism, 16, 385  
 hypotonia, 235  
 hypovolemia, 36, 134, 275t, 430  
 hypoxemia, 611–12  
 hypoxia, 506, 627  
 hysterectomy, 384
- ibuprofen, 161  
 ileal disease, 23, 57t, 62, 193, 201t, 464t  
 ileal plasmacytoma, 320t  
 ileal pouch, 353, 368  
 ileal resection, 201t, 243, 315t  
 ileitis, 216, 310f  
 ileocecal sphincter, 229, 245t, 363f  
 ileostomy, 368  
 ileum, 34, 180, 208  
 ileus: colonic, 375, 390; and cystic fibrosis, 454; distension, 231; gallstone, 472; and islet cell tumors, 450; meconium, 455t, 456; nutritional intervention, 70; pancreatitis, 77; paralytic, 471  
 illness behavior, 30  
 immunoproliferative small intestinal disease, 255  
 immunosuppression, 217, 218t, 255. *see also* HIV  
 immunosuppressive agents: to treat Crohn's disease, 323, 325t, 326–8, 330; to treat ischemia, 287; and liver transplantation, 638–41; to treat sclerosing cholangitis, 484; to treat small bowel tumors, 255; to treat ulcerative colitis, 352  
 Imodium®, 323, 340, 348  
 impotence, 502t, 588  
 incapacity, 4  
 incontinence, 18–19, 381–4  
 indigestion. *see* dyspepsia  
 indinavir, 291  
 indirect pancreatic function tests, 424t, 425–6  
 indocyanine green, 527  
 indole compounds, 245  
 indomethacin, 161, 523t, 612  
 infants. *see also* children; absorption, 198; Alagille's syndrome, 732; amylase deficiency, 198; apnea, 694; biliary atresia, 482; celiac disease, 239; cholestasis, 481, 728t, 729–34; cirrhosis, 731; constipation, 358, 698–9; Crigler-Najjar syndrome, 529; cystic fibrosis, 454, 457, 719–22; defecation, 696; dehydration, 713; diarrhea, 22, 217, 711, 713, 718–19; dietary therapy, 710, 717; enzyme deficiency, 656; failure to thrive, 720; feeding, 705; fibrocystic disorders, 480–1; GERD, 692–5; growth, 703–10; hepatitis, 536; hypertrophic pyloric stenosis, 172; jaundice, 722, 725–35; malnutrition, 701–3; meconium ileus, 719; obstruction, 358; pancreatic insufficiency, 724; premature, 704; rehydration therapy, 716; rotavirus, 219; Sandifer's syndrome, 694; vitamin deficiency, 58t; vomiting, 686  
 infection: anorectal, 407; biliary. *see* cholangitis; colonic, 388–92; fungal infection, 295–7; *H. pylori*, 149, 173; herpes, 294t, 295, 301; HIV-related, 292–303, 293t–4t, 303, 305; mycobacterial, 292–5; parasitic, 220, 222, 297–9; post-surgical, 641–2; respiratory, 627; urinary, 627; viral, 300–2, 429t  
 inflammatory bowel disease, 38. *see also* Crohn's disease; ulcerative colitis; children, 687t, 706t, 712; causing diarrhea, 20, 21t, 211; dietary therapy, 62–3; and GI bleeding, 34, 35t, 410t, 413t; and ischemic colitis, 284–5; malnutrition, 64t; manifestations of, 316t; therapy for, 325t  
 infliximab, 314, 325t, 328, 347, 573  
 informed consent, 80, 84–6  
 Infufer®, 346  
 innervation, 89. *see* nerve supply  
 insecticides, 430t  
 institutional review committee, 86  
 insulin, 50, 55–6, 77, 204, 208t, 573, 575, 579  
 insulinoma, 450  
 interferon, 250, 304, 540, 556t, 558, 562t–3t, 564–5, 565t, 643, 649  
 interleukins, 168–70  
 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 79  
 International Normalized Ratio (INR), 36, 507, 599. *see* prothrombin time (PT) test  
 intestinal bypass, 201t  
 intestinal ischemia, 24  
 intestinal metaplasia, 169–70  
 intestinal resection, 201t, 226t  
 intestine, small. *see* small intestine  
 intra-abdominal malignancy, 47  
 intracellular transport, 499  
 Intralipid®, 212t  
 intramural diverticulosis, 133

- intravenous drug use, 290, 292, 300, 304  
intrinsic factor, 141, 143, 150, 180  
introns, defined, 743  
intussusception: children, 686; with cystic fibrosis, 454, 456; causing obstruction, 222, 255, 376  
iodine, 56, 203t  
iodoquinol, 222, 294t, 392  
ions. *see* electrolytes  
irinotecan, 171  
iritis, 316t, 319, 345t, 348  
iron: absorption, 182–3, 184f; and celiac disease, 62; excess, 55t, 65t, 588, 596; malabsorption, 208; replacement, 210t; sources, 182–3; storage disorder, 586  
iron deficiency: blood loss, 34; and celiac disease, 235t, 236–7; with colon cancer, 365t, 366; with Crohn's disease, 315t, 321; and esophageal webs, 7, 131; and GI bleeding, 37; and hiatus hernia, 103; and hookworms, 393; with inflammatory bowel disease, 317t; with irritable bowel syndrome, 380; and malassimilation, 203–4t; and malnutrition, 23, 56; manifestations of, 206; neoplasms, 128t; with ulcerative colitis, 335, 344t, 346; and whipworm, 393  
irritability, 206, 235, 624  
irritable bowel syndrome: and bloating, 15–16; causes, 377; chronic diarrhea, 21t; chronic abdomen, 28–9; constipation, 16–17, 385; diagnosis, 377–8; causing diarrhea, 20, 209, 226t; mucus stool, 399; therapy, 380–1, 382t  
irritable esophagus, 125  
ischemia: about, 258; and acute abdomen, 27; acute arterial, 265–73, 273–4; causing acute hepatitis, 530t; acute mesenteric, 252–4; caused by thrombosis, 243; causes, 275t; chronic mesenteric, 254, 274–6; classification of, 258–60, 259f; clinical presentation, 265–6; and Crohn's disease, 28, 320t; and diarrhea, 211; focal segmental, 279; and gastritis, 151; GI bleeding, 35t, 410t, 413t; investigation, 266–9; and liver transplantation, 641; nongangrenous, 276–87; pathophysiology of, 263–5; with peritonitis, 264–5, 269, 270f; prognosis, 273; and protein-losing enteropathy, 249; and short bowel syndrome, 76; treatment, 269–73  
ischemic colitis. *see* ischemia;  
nongangrenous ischemic colitis  
ischemic heart disease, 108  
ischemic hepatitis, 506, 658  
islet cell tumors, 19, 21t, 450–1  
islets of Langerhans, 418  
Isocal®, 212t  
isomaltose, 197, 232  
isoniazid, 57t, 293t, 523t, 566, 582, 584  
Isospora belli, 294t, 299  
isphagula, 385  
Ito cells, liver, 493, 603  
itraconazole, 293t  
ivermectin, 394  
jaundice: about, 30–2, 501–3, 725; acute abdomen, 26; and alcoholic liver disease, 570; in biliary disease, 505; children, 725–35; cholecystitis, 471; choledocholithiasis, 473; and cholestasis, 595; and cholestasis of pregnancy, 655; cholestatic, 513f; cholestatic hepatobiliary disease, 31; and cirrhosis, 592, 599, 601; with cirrhotic ascites, 614; evaluation, 732–4; and hepatitis, 566; hyperbilirubinemia, 501–3; management, 734–5; neonatal, 722, 725–35; pancreatic diseases, 432, 445; pathological, 726–32; physiological, 726; ulcerative colitis, 346  
jejunitis, 201t  
jejunoileal bypass, 201t  
jejunoileitis, 241  
jejunum, 71, 182, 189, 255  
Kaposi's sarcoma, 152t, 302  
Kasai procedure, 482, 731  
Kayser-Fleischer ring, 518, 530t, 586  
keratoconjunctivitis sicca, 559  
keratomalacia, 203t, 205t  
kernicterus, 529  
ketoacidosis, 427t  
ketoconazole, 113, 293t, 526t  
ketones, 54  
ketoprofen, 161  
ketosis, 654  
kidney: enlarged, 39; hepatorenal syndrome, 571, 629–32; transplantation, 640  
kidney failure. *see* renal failure  
kinase, 250  
Klebsiella, 621t  
koilonychia, 207  
Krukenburg tumor, 170  
KuZyme HP®, 211t  
kwashiorkor, 55, 60t, 206  
labetol, 523t  
Lactaid®, 234

- lactase, 19, 64t, 198–9, 227, 234, 244, 323  
 lactate dehydrogenase, 207, 265  
 lactic acid, 122, 227  
 lactitol, 628  
 Lactobacillus, 364, 621t  
 lactose: absorption, 194–5; and celiac disease, 236; causing diarrhea, 19, 213t, 225; dietary therapy, 60–3; and disaccharidase deficiencies, 232; enteral nutrition, 73; intolerance of, 60, 62–3, 71, 236, 321, 379; and malnutrition, 59  
 lactulose, 19, 213t, 227, 573, 628, 701, 702t  
 lamivudine, 304, 556t, 558, 565, 616. *see also* 3TC  
 Langerhans cell histiocytosis, 151  
 laparoscopy, 27  
 laparotomy, 253  
 laryngitis, 97  
 laryngoscopy, 116  
 laryngospasm, 694t  
 larynx, 90–1, 97, 112, 117, 126, 392–3  
 laser therapy, 127, 130  
 lavage: colonic, 628; peritoneal, 436  
 lax bowels. *see* diarrhea  
 laxatives: abuse, 232; children, 701; to treat constipation, 18–19, 385–6, 628, 701, 701t; causing diarrhea, 20, 21t, 213t, 225, 226t, 227, 232; osmotic, 19, 382t; and ulcerative colitis, 341t  
 LCAT. *see* lecithin-cholesterol acyltransferase (LCAT)  
 LDL, 53–4  
 lecithin, 461–2, 579  
 lecithin-cholesterol acyltransferase (LCAT), 53  
 legs, weak, 23  
 leiomyoma: esophageal, 125, 126t; small intestine, 255  
 leiomyosarcoma: esophageal, 126t; small intestine, 255  
 LES. *see* esophageal sphincter, lower  
 lesions: angiodysplastic, 410; annular, 255; anorectal, 396; apple-core, 376; with celiac disease, 239–40; Dieulafoy, 34, 165; eye, 316t; hepatic, 346, 457, 644–5, 649–51; with Kaposi's sarcoma, 302; mass, 276t; oral, 113; polypoid distal, 255; prolapsing, 398; pseudolymphoma, 173; pseudomembrane, 224; PUD, 153; pulmonary, 295; skin, 347; skip, 308; small intestine, 234; spinal cord, 217t; structural, 116; submucosal, 127; tumor-like, 126t  
 leucine zipper, 769  
 leukemia, acute, 275t  
 leukocytosis, 265, 285, 321, 340; biliary colic, 467t; cholecystitis, 471–2; choledocholithiasis, 474; Crohn's disease, 323; ischemia, 253; toxic megacolon, 345t; ulcerative colitis, 334–5, 346  
 leukopenia, 327, 572  
 levodopa, 628  
 libido, 203t  
 lichen planus, 559  
 lidocaine, 523t  
 lifestyle modification, 109, 123; 168, 123  
 ligament of Treitz, 34  
 ligation, 608  
 lignins, 195  
 limy bile, 473  
 linitis plastica, 152t  
 linoleic acid, 74, 203t, 455  
 Linton-Nachlas tube, 607  
 lipases, 27, 56, 192, 305, 421, 442, 471  
 lipid solutions, 23, 74  
 lipids, 53, 507  
 lipolysis, 50, 54–6, 192  
 lipoma, small intestine, 255  
 lipoprotein: chylomicrons, 193; metabolism, 52f; role of liver, 493  
 lipoprotein lipase, 53  
 lipoxigenase products, 190t  
 lithium, 231  
 lithocholic acid, 245–6  
 lithotripsy, 475–6  
 liver. *see also* fatty liver; abdominal mass, 39; abnormal chemistry, 303; anatomy and function, 493–500; bile acid production, 193; diagnostic tests, 505–11; and E. histolytica, 391; enlarged. *see* hepatomegaly; evaluation, 513–14; examination of, 45–6; gluconeogenesis, 53; hyperbilirubinemia, 527–30; indications, 600; inherited, 585–9; LDL catabolism, 54; morphology, 491–3; neoplasms, 643–51; nutritional disorders, 55–6; portal hypertension, 601–12; results and future, 642–3; structure and function, 491–500; transplantation. *see* liver transplantation; vascular disorders, 658–61  
 liver disease. *see also* specific types; abscess, 222; biliary, 316t; cholestatic, 64; chronic, 32–3, 552, 584–5, 606; clinical features, 501–5; with Crohn's disease, 319; with cystic fibrosis, 457; diagnosis, 4, 511–21; dietary therapy, 63–5; drug-induced, 579–85; and fat malabsorption, 193; and GI bleeding, 36; and HIV, 303–5; and



- jaundice, 31; and malassimilation, 201t; nutritional intervention, 71; in pregnancy, 651–7; and protein deficiency, 206; total parenteral nutrition (TPN), 75
- liver failure, 63, 532, 541, 548, 566, 624, 627, 653
- liver transplantation: about, 632; complications, 640–2; contraindications, 635t; indications, 481, 485, 531, 541, 548, 574, 579, 610, 612, 620, 623, 629, 632–4; living donors, 636–7; model for end-stage liver disease, 635–6; postoperative management, 637–40; and pregnancy, 654; procedure, 637; workup, 634
- lobules, 419f, 596
- Lomotil®, 323, 340, 348
- loperamide, 218t, 294t, 323, 348, 382t, 384, 389
- lorazepam, 523t
- Lucey-Driscoll syndrome, 727
- lumbar lordosis, 15
- lump in throat. *see* globus
- Lundh test, 425
- lung consolidation, 97, 107
- lung disease, 250, 453, 585, 719
- lupus erythematosus, 117t, 389
- lye, 115, 131
- lymph nodes, enlarged, 128
- lymphadenopathy, 26, 292, 408
- lymphangiectasia, 194, 201t
- lymphangioma, esophageal, 126t
- lymphatic drainage: anal canal, 395–6; esophagus, 89; small intestine, 175; stomach and duodenum, 141
- lymphocytic colitis, 151, 394
- lymphocytic gastritis, 152t
- lymphogranuloma venereum, 22, 303
- lymphoma, 152t; bacterial overgrowth syndrome, 245t; B-cell, 303; and celiac disease, 235t, 239, 241–2; causing cholestasis, 595; with Crohn's disease, 151; causing diarrhea, 21t, 229t, 233t; drug-induced, 328; and fat malabsorption, 194; gastric, 149, 171; and gastritis, 151; causing GI bleeding, 34t; hepatitis C, 559; HIV-associated, 303; intestinal, 237, 320t; and malassimilation, 201t; malnutrition, 54t; small intestine, 255; and sprue, 241
- lysine, 745
- lysolecithin, 430, 471
- lysosomes, 420
- macroamylasemia, 427t
- macrocytosis, 236
- macronodular cirrhosis, 571–2, 598, 599f
- macronutrients, 50
- magnesium: and Crohn's disease, 324; deficiency, 204t, 235t; causing diarrhea, 19–20, 225; malabsorption, 207; malnutrition, 77; replacement, 210t
- magnesium hydroxide, 19, 701, 702t
- magnesium sulfate, 227t
- magnetic resonance  
 cholangiopancreatography (MRCP), 475f, 476
- magnetic resonance imaging, 510
- malabsorption. *see also* malassimilation; malnutrition; about, 202; and bacterial overgrowth syndrome, 247; calcium, 207; of carbohydrates, 198–9, 226t; clinical signs and symptoms, 202; with Crohn's disease, 314, 315t; causing diarrhea, 19–20, 211, 226t; dietary therapy, 62, 64; drug-induced, 64t; of fat, 193, 198, 315t, 319, 724; of glucose, 197; with HIV, 306; inflammatory bowel disease, 64t; in liver disease, 502t; and lymphoma, 255; magnesium, 207; and malnutrition, 23, 59; and parasitic enteritis, 219; postgastrectomy, 244; vitamin D, 207; vitamin deficiency syndromes, 57t; and Whipple's disease, 251
- malaise, 216, 218, 501, 502t, 531–2, 537, 542, 559, 576, 641
- malassimilation. *see also* malabsorption; maldigestion; carbohydrate, 202–6, 235t; and celiac disease, 235t; classification of, 201t; diagnostic approach, 207–9; causing diarrhea, 211; of fat, 206, 235t; of iron, 206–7; therapy for, 208t, 210t
- maldigestion. *see also* malassimilation; about, 23, 202; clinical signs and symptoms, 202–3; causing diarrhea, 226t; postgastrectomy, 244; of starch, 198
- malignant melanoma, esophageal, 126t
- Mallory-Weiss tear, 34, 97, 134, 165
- malnutrition. *see also* malassimilation; nutrition; about, 22–3; albumin, 67; and alcoholic liver disease, 570–1; assessment, 65–8; causes, 54t, 55–6; and celiac disease, 236; children, 701–10; with Crohn's disease, 314, 315t; causing diarrhea, 20, 211; effects on GI tract and pancreas, 56–9; effects on the intestine, 60t; and HIV, 304; with inflammatory bowel disease, 62, 64t, 316t; kwashiorkor, 55; marasmus, 55–6; nutrition support, 76–7

- MALT (mucosa-associated lymphoid tissue) syndrome, 149, 152t, 171
- maltase, 195
- maltose, 420
- maltotrioses, 232, 420
- manganese, 56
- Manning criteria, 378–9
- mannitol, 19, 225, 227t, 627
- manometry, esophageal, 99, 108, 110, 118f, 123, 124f
- marasmus, 55–6, 206
- marsupialization, 407
- mass, abdominal. *see* abdominal mass
- mastocytosis, 201t
- Meckel's diverticulitis, 320t
- Meckel's diverticulum, 155, 249–50
- meconium ileus, 455t, 456, 719
- mediastinal tumor, 7
- mediastinoscopy, 129
- Medical Research Council of Canada (MRC), 80
- megacolon: aganglionic. *see* Hirschsprung's disease; and constipation, 18; toxic, 217, 221, 285–7, 316t, 323, 334–6, 340, 342–3, 344t–5t, 348
- megaloblastosis, 207–8
- megarectum, 387
- Meissner's plexus, 90, 141, 176
- melanosis coli, 18, 232
- melena, 33, 134, 165, 279, 365t, 366, 397, 409. *see also* blood in stool
- memory loss, 571
- menadione. *see* vitamin K3
- Ménétrier's disease, 148t, 152
- meningismus, 216
- menstruation, 15, 29, 379
- mental apathy, 206
- mental retardation, 527
- meperidine, 436
- 6-mercaptopurine, 325t, 327
- mercaptopurine, 429t, 526
- Meritene Powder®, 212t
- mesalamine, 325t, 327, 329–30, 349, 352
- Mesasal™, 327, 349–50
- mesenteric adenitis, 216
- mesenteric arterial occlusion: clinical presentation, 265–6; investigation, 266–9; treatment, 269–73
- mesenteric arteries: anatomy, 260–1; blood flow, 261–3; occlusion, 265–73
- mesenteric insufficiency, 151
- mesenteric ischemia. *see* ischemia
- mesenteric vasculature, 260–5
- mesenteric veins: anatomy, 260–1; occlusion, 253–4, 260; thrombosis, 252, 254, 274
- mesenteric venous occlusion, 273–4
- messenger RNA: and DNA mutations, 759–64; gene sequences, 743; post-transcription processing, 772–80; transcription, 739, 769–71; translation, 782–7
- metabolic disturbances, 17t, 434, 638
- metabolic myopathy, 117t
- metabolism: carbohydrates, 51f; fat, 51f; lipoprotein, 52f; protein, 51f; role of liver, 524–6
- metaplasia, myeloid, 659
- METAVIR system, 548–9,
- metformin, 579
- Methanobrevibacter smithii, 13
- methionine, 245
- methotrexate: causing diarrhea, 225; to treat inflammatory bowel disease, 314, 325t, 326–58 *passim*; causing liver disease, 579, 584
- methylcellulose, 385
- methyl dopa, 341t, 566, 582, 584
- methyltestosterone, 583
- methysergide, 250
- metoclopramide: as anti-emetic, 12; to improve gastric emptying, 173
- metoprolol, 523t
- metronidazole: to treat amebiasis, 222, 392; to treat bacterial overgrowth, 248; to treat choledocholithiasis, 476; to treat colon infections, 390, 392; to treat Crohn's disease, 323, 325t, 329–30; to treat hepatic encephalopathy, 628; to treat HIV-related infections, 294t; to treat inflammatory bowel disease, 353; to treat Microsporidium, 299; to treat parasitic infections, 220, 222, 297; to treat pseudomembranous colitis, 224
- micelles, 60, 192, 462
- microcytosis, 37
- miconodular cirrhosis, 571, 597–8
- microscopic colitis, 394
- Microsporidium, 294t, 298, 305
- midesophageal diverticula, 133
- midodrine, 632
- migrating motor complex, 177
- milk of magnesia, 382t
- milk protein enteropathy, 706t
- Milkman's fractures, 207
- Milwaukee classification, 479
- mineral oil, 701, 702t
- minerals: absorption, 178–83; deficiency, 205t; replacement, 210–11t

- Mirizzi's syndrome, 466  
 misoprostol, 382t  
 mittelschmerz, 29  
 MMF, 639  
 model for end-stage liver disease (MELD), 635–6  
 molecular medicine, 738  
 molybdenum, 56  
 monoglycerides, 192–3  
 monomeric formulas, 71, 77  
 monosaccharides, 50, 196f, 201t  
 montelukast sodium, 114  
 Morgagni's columns, 395  
 morphine, 479, 523t  
 motility: colon, 361; esophagus, 7, 120–3, 134; gallbladder, 478; parenteral nutrition, 76; small intestine, 177–8, 228; stomach, 142–3  
 motor disorders, esophagus, 6–7, 119–23  
 mouth-to-anus capsule, 208  
 MRC. *see* Medical Research Council of Canada (MRC)  
 mRNA. *see* messenger RNA  
 mucin, 463  
 mucocele, appendiceal, 320t  
 mucoepidermoid carcinoma, esophageal, 126t  
 mucosa-associated lymphoid tissue (MALT) syndrome, 149, 152t, 171  
 mucosal carcinoma, 112  
 mucosal defence mechanisms, 155  
 mucosal inflammation, 313f  
 mucus: and cholelithiasis, 463; in gastric juice, 143; inflammation, 221; secretion of, 141; in stool, 211, 377–9, 386, 399  
 multiple sclerosis, 17, 117t  
 mumps, 429t  
 Münchausen syndrome, 30  
 Murphy's sign, 471–2  
 muscle atrophy, 206  
 muscle catabolism, 64  
 muscle tenderness, 204t  
 muscle wasting: with carbohydrate malassimilation, 203t–4t; with cirrhotic ascites, 614; with hepatic encephalopathy, 624; and malnutrition, 23, 56; and nutritional assessment, 69t; and pancreatitis, 438; and protein malassimilation, 206  
 muscular dystrophy, 117t  
 muscularis mucosa hypertrophy, 316t  
 myalgia, 219  
 myasthenia gravis, 117t  
 Mycobacterium avium-intracellulare, 291–2, 293t  
 Mycobacterium tuberculosis, 149, 293t, 295  
 mycophenolate mofetil, 639  
 myeloproliferative disorders, 602t, 659  
 myenteric plexus, 90, 141, 176, 387–8  
 myocardial infarction, 253, 276  
 myoclonus, 624  
 myopathy: metabolic, 117t; proximal, 205t  
 myotomy: cricopharyngeal, 118, 131–2; and diverticula, 133; esophageal, 8, 121; Heller, 122; pyloric, 173  
 myotonic dystrophy, 17  
 Na<sup>+</sup>/K<sup>+</sup>-ATPase pump. *see* sodium pump  
 nails, 204t, 207  
 naproxen, 161  
 narcotics, 600, 627  
 nasal erosions, 72  
 nasal regurgitation, 95  
 nasoenteric feeding, 72–3  
 nasogastric suction, 323, 343, 436, 456  
 nausea: about, 9–12; and acute abdomen, 25; and alcoholic liver disease, 570; and ascites, 33; and cholecystitis, 305; and diarrhea, 214–15, 218–19; and diverticulitis, 373; drug-induced, 350; and gastritis, 146–7; with HIV, 297; and hookworms, 393; inflammatory bowel disease, 64t; with ischemia, 253; and jaundice, 31; and nasoenteric feeding, 73; and NSAIDs, 160; with pancreatic diseases, 445; and pancreatitis, 432; in pregnancy, 654, 656; with small bowel obstruction, 318; with Strongyloides stercoralis, 299  
 neck surgery, 117t  
 necrosis: acute tubular, 631; caustic chemical ingestion, 115; cholecystitis, 472; and enteral nutrition, 72; and gastritis, 150, 152; and ischemic colitis, 285, 287; liver, 596; of the pancreas, 434; toxic, 581–2  
 neoadjuvant therapy, 127  
 neomycin, 201t, 628  
 neonatal hepatitis, 585  
 neonates. *see* infants  
 neoplasms. *see also* specific types; anal, 303, 397; anorectal, 397; appendiceal, 250; benign, 125–7; biliary, 486–7; brain, 11; brainstem, 117t; carcinoid, 320t; in celiac disease, 235t; classification of, 126t; colonic, 399, 403; with Crohn's disease, 318, 320t; diagnosis, 4, 170; and diarrhea, 222; drug-induced, 584–5; esophageal, 95–7, 112, 122, 125–30; gallbladder,

- 479–80; gastric, 144t, 149, 154f, 168–71; and GI bleeding, 34, 410t, 413t; head and neck, 117t; and hemorrhaging, 165; hepatic, 515t, 521, 643–51; HIV-associated, 291, 302–3; hypopharyngeal, 131; intestinal, 28, 243, 250, 253, 255, 320t; with ischemic bowel disease, 28; islet cell, 19, 21t, 226, 444, 450–1; liver, 643–51; mediastinal tumor, 7; neurogenic, 171; oropharyngeal, 117t; pancreatic, 427t, 444; prevention, 171; rectal, 303, 398–9, 403; screening for, 368–9; skin, 764; small bowel, 243, 255, 320t; treatment, 170–1
- Neoral®, 638–9
- neostigmine, 375
- nephrolithiasis, 243, 317t, 319
- nephropathy, 571
- nephrotic syndrome, 68
- nerve supply: to anal canal, 396; to colon, 358–60, 386; to esophagus, 89, 94; to pancreas, 417; to small intestine, 176; to stomach and duodenum, 141
- neurogenic tumors, 255
- neuroleptic agents, 275t
- neuromuscular disease, 7
- neurotensin, 190t
- neurotransmitters, 93–4, 188, 190, 230, 358, 625
- neutropenia, 304
- nevirapine, 291
- niacin, 57t, 203t–5t
- nicotine, 525t
- night blindness, 58t, 203t, 205t
- night sweats, 292, 296, 303
- Nissen fundoplication, 109, 695
- nitrates, 109, 121–2, 124, 133
- nitrites, 287
- nitrofurantoin, 566
- nitrogen, 68–9, 71
- nitroglycerin, 134
- nitrosamines, 444
- nodular regenerative hyperplasia, 645
- nongangrenous ischemic bowel disease: causes, 276–9; colitis, 279–87; etiology, 276–9; focal segmental ischemia, 279
- nongangrenous ischemic colitis: clinical presentation, 279–86; figures, 281f–5f; pathogenesis, 279; treatment, 286–7, 286–7
- nongranulomatous ulcerative jejunoileitis, 320t
- norepinephrine, 190, 192
- nortriptyline, 382t, 523t
- Norwalk virus, 213t, 218–19
- NSAIDs: avoided in cirrhosis, 600; and bleeding, 36, 165; to treat cholecystitis, 472; cytochromes, 525t; and gastric duodenal disease, 160–2; and gastritis, 145, 148t, 150; and *H. pylori*, 157–9; mechanism, 161; and PUD, 28, 155; risk factors, 160t; selection of, 162t
- nucleosomes, 745
- 59-nucleotidase, 506, 591, 651
- nutrient deficiency. *see* malnutrition
- nutrient-dependent transport, 185–6, 187f
- nutrient-independent transport, 187–9
- nutrition. *see also* diet; malnutrition; assessment, 65–8; body composition, 66; body weight, 66; creatinine-height index (CHI), 66; and Crohn's disease, 324; energy requirements, 69–70; enteral, 70–3; essential concepts, 49–54; and HIV, 305–6; immune competence, 68; intervention, 65–77; liver, 55t; malnourished patient, 76–7; methods of assessment, 67t; nitrogen requirements, 68–9; oral refeeding, 70; plasma proteins, 66; subjective global assessment (SGA), 66, 69t; total parenteral nutrition (TPN), 70, 73; tube feeding, 70; weight loss, 66
- nutritional polyneuropathy, 23
- nystatin, 113
- obesity: and alcoholic liver disease, 568; and cholecystitis, 463; and cholelithiasis, 464t; and cholesterol, 463; GERD, 109–10; liver disease, 55t, 517, 551t, 561, 568, 574, 576; nutrition, 70; causing pancreatic cancer, 444t
- obstipation. *see* constipation
- obstruction. *see also* pseudo-obstruction; arterial, 271; biliary, 28, 193, 465, 470–4, 597, 688t, 723, 730, 734; bowel, 28, 255; causes, 376–7, 690; cholecystitis, 470–1; clinical features, 24–5, 31, 39, 44; colonic, 14, 25, 59, 63, 70, 374–7; and constipation, 16, 374, 385; and cystic fibrosis, 455t, 456, 721–2; and diarrhea, 374–5; and distension, 231; esophageal, 95, 114, 131, 134; gallstone ileus, 472; gastric, 688t; hepatic, 660; intestinal, 392, 684, 686, 689, 700t, 719, 721, 728t, 729; causing ischemia, 276t; and jaundice, 31, 32f; lymphatic, 47; pancreatic, 418, 420, 429–30, 432; post-ampullary, 688t; sinusoid, 660; small bowel, 317–18; small intestine, 375
- occlusion, mesenteric. *see* ischemia

- occult bleeding, 34  
octreotide, 152, 250, 252, 294t, 298–9, 442, 607, 632, 649  
odynophagia: about, 6, 95; with esophageal neoplasms, 128; in esophagitis, 113, 116; in GERD, 107; HIV-associated, 295, 300–1  
ofloxacin, 621  
Ogilvie's syndrome, 375–6  
OKT3, 639, 641  
oligomeric formulas, 71  
oligopeptides, 199–200  
oligosaccharides, 71, 195, 198–9  
oliguria, 629  
olsalazine, 350  
omeprazole: to treat dysphagia, 7; to treat GI bleeding, 167  
opaque calculus, 27  
opiates, 17  
opioids, 592  
optic neuritis, 392  
oral contraception, 253, 275t, 279  
oral refeeding, 70, 717  
organ donation, 636  
organ transplantation, 640–1  
ornithin aspartate, 628  
oropharyngeal incoordination, 117t  
oropharyngeal inflammation, 117t  
oropharynx, 244, 295, 302  
Osmolite®, 212t  
osteomalacia, 58t, 207–8, 235t, 236  
osteopenia, 206  
osteoporosis, 592–3  
otitis media, 72  
ovarian cysts, 320t  
ovarian disease, 25  
overhydration, 73  
owl-eye, 147  
oxalate, 206, 243, 319  
oxaluria, 206  
oxazepam, 523t  
oxidation, 54, 60  
oxidative stress, 575, 579  
oxygen bridge, 194–5  
oxygen therapy, 612  
oxyntic cells, 141  
oxyphenisatin, 566  
paclitaxel, 171  
pain, abdominal: abdominal mass, 38; acute abdomen, 24–5; arterial occlusion, 266; ascites, 614; biliary, 463, 465–6, 467t, 481; celiac disease, 235t, 236, 241; cholangitis, 483–4; cholecystitis, 305, 470–2 passim, 478; cholecystoses, 479; cholelithiasis, 428, 463, 465, 474; chronic abdomen, 28–30; cirrhotic ascites, 614; colitis, 280; colon cancer, 25, 365t; constipation, 17, 385, 700t; Crohn's disease, 314, 315t, 317, 339, 342t; cystic fibrosis, 454, 456; and diagnosis, 3; and diarrhea, 214–19 passim, 221, 224, 234; diverticular disease, 28, 373; fatty liver, 569, 576; gallbladder cancer, 480; gastric volvulus, 172; GI bleeding, 410; graft-versus-host disease, 150; hepatitis, 531; HIV-associated, 291, 297; hookworms, 393; inflammatory bowel disease, 38, 40, 64t; irritable bowel syndrome, 29, 377–80 passim, 382t; ischemia, 28, 253–4, 264–5, 274, 279; lactase deficiency, 60–1; liver disease, 503, 652, 655; liver neoplasms, 504, 644, 646; malassimilation, 207; menstruation, 29; at night, 28; nonspecific, 258; and NSAIDs, 160; obstruction, 318, 374–6 passim, 721; pancreatic, 417–18, 432, 434, 437–8, 445, 452, 722; parasites, 393; peritonitis, 621; postprandial, 64t, 266, 437, 441; postsurgical, 485; PUD, 28; renal, 29; Shigella, 388; Strongyloides stercoralis, 299, 393; therapy for, 382t; toxic megacolon, 340; tumors, 255; ulcerative colitis, 331, 334, 339, 342t, 346; vomiting, 688t, 690; in Whipple's disease, 250  
pain, anorectal: anal carcinoma, 303; causes, 396–7; Chlamydia, 408; and diarrhea, 212, 216; fissures, 400; hemorrhoids, 403; herpes, 408; in homosexual men, 303; proctalgia fugax, 40–1  
pain, back: and acute abdomen, 25; and dysphagia, 95; esophageal cancer, 95; pancreatic, 28, 445, 722  
pain, biliary, 25, 28, 465, 478–9  
pain, bone, 204t–5t, 207, 236  
pain, chest: achalasia, 122; Boerhaave's syndrome, 134; Candida esophagitis, 113; and diverticula, 133; and dysphagia, 95; esophageal disorders, 5, 96, 113, 115–16, 119, 121, 123–5; food-bolus obstruction, 134; with GERD, 107–8; nausea and vomiting, 11; neoplasms, 125, 128; nutcracker esophagus, 121; portal hypertension, 608; testing, 98–9; trauma, 134; and vomiting, 11  
pain, epigastric, 8, 10, 28, 146–7, 445  
pain, joint, 204t  
pain, kidney stones, 11  
pain, muscle, 204t

- pain, on swallowing. *see* odynophagia  
 pain proneness, 30  
 pain, somatic, 24  
 pain, visceral, 24, 466  
 palliation: gastric cancer, 170; esophageal neoplasms, 7, 127, 130; gallbladder cancer, 480; for pancreatic carcinoma, 449  
 pallor: celiac disease, 235; children, 714t; cholelithiasis, 466; GI bleeding, 35; iron deficiency, 207; malassimilation, 203t  
 palmar erythema, 31, 502t, 566, 570–1, 651  
 palpation: abdomen, 25–6, 44; abdominal mass, 38, 375; for ascites, 47; liver, 45; pelvic organs, 40; rectal, 400; spleen, 46  
 pancreas: abdominal mass, 39; anatomy, 417–18; carcinoma, 443–50; diabetes, 424, 426–7, 437, 444t, 445–6, 450–1; fetal development, 452f; function tests, 423–8; islet cell tumors, 450–1; and jaundice, 31; malnutrition, 56–9; neoplasms, 427t, 450–1; physiology, 419–23; role in digestion, 180; secretion, 423; therapy for, 208t  
 pancreas divisum, 452  
 Pancrease\*, 211t, 442  
 pancreatic resection, 201t  
 pancreatectomy, 449  
 pancreatic atrophy, 423  
 pancreatic calcification, 27, 423  
 pancreatic carcinoma, 201t  
 pancreatic cholera, 19, 451  
 pancreatic insufficiency: and celiac disease, 241; children, 718, 723–4; cystic fibrosis, 455–7, 718–22; diagnosis, 423; causing diarrhea, 226t; dietary therapy, 71, 211t; malabsorption, 193, 198, 244; malassimilation, 201t, 207–8; management, 723–4; tests, 423–8; vitamin deficiency syndromes, 57t  
 pancreatic polypeptide, 423  
 pancreatic replacement therapy, 442, 443t, 455t, 457–8  
 pancreatitis: acute, 431t, 432–7; and acute abdomen, 26; alcohol-induced, 420; causes, 420, 429t; and choledocholithiasis, 473–4; chronic, 437–43; and chronic abdomen, 28, 201t; clinical features, 28, 432, 437–738; complications, 433–4, 438–9; cystic fibrosis, 456, 722; diagnosis, 434–5, 440–1; causing diarrhea, 21t; dietary therapy, 73, 77; drug-induced, 327; and enzyme secretion, 420; evaluation of, 434–5, 440; gallstone, 466, 477; HIV-associated, 305; interstitial, 430; causing ischemia, 275t; and malassimilation, 207; and pancreas divisum, 418; pathogenesis, 428–33; and portal vein thrombosis, 433t, 661; treatment, 436–7, 441–3  
 pancreatoduodenal resection, 449  
 pancreatojejunostomy, 442  
 pancreolauryl test, 426  
 pancreozymin, 421f  
 pancytopenia, 57t  
 pantothenic acid, 57t  
 papaverine, 271–2, 287  
 para-aminobenzoic acid, 426  
 paracentesis, 33, 615t, 618  
 paralyzed intestines, 16  
 paraparesis, spastic, 624  
 parasites: causing achalasia, 122; in biliary tract, 465, 591; in children, 706t; causing cholangitis, 483; and cholelithiasis, 465; and cholestasis, 591; in colon, 331, 391–4; causing diarrhea, 21t, 22, 213t, 233t; enteritis, 219–22; gastritis, 150; GI tract, 148t, 150–1, 292; HIV-associated, 292, 294t, 297–9, 297–300; malassimilation, 208; causing neoplasms, 486; causing pancreatitis, 429  
 parasthesia, 205t  
 parenteral nutrition, 59. *see* total parenteral nutrition (TPN)  
 paresthesias, 23, 204t, 207, 329  
 Parkinson's disease, 17, 117t  
 paromomycin, 294t, 298  
 parotid enlargement: in cirrhosis, 571; in liver disease, 502t; in malassimilation, 203t  
 partial thromboplastin time, 36  
 parvovirus, 213t  
 Paterson-Kelly (Plummer-Vinson) syndrome, 7, 131, 207  
 pathophysiologic defects, 153t  
 patient autonomy, 85  
 patient rights, 79  
 patient–doctor relationship, 30, 290  
 pectin, 195  
 peliosis hepatis, 583t  
 pellagra, 57t, 250  
 pelvic floor dyssynergia, 388  
 pelvic inflammatory disease, 25, 29, 320t  
 pemphigoid, 114  
 pemphigus, 114  
 penicillamine, 57t, 341t, 484, 586  
 penicillin, 390  
 pentamidine, 305, 429t  
 Pentasa\*, 327, 349–50  
 pentaspan, 618

- pentazocine, 523t  
 pentoxifylline, 573  
 pepsin: and celiac disease, 234; in digestion, 145; in gastric juice, 109, 143; and GERD, 109; hydrolysis, 199; and PUD, 155; role in PUD, 155; secretion of, 141, 143, 199  
 pepsinogen, 141, 144–5, 199  
 pepsinogenemia, 160  
 peptic stricture, 110–11  
 peptic ulcer disease (PUD): bleeding, 34t, 36, 157, 165; causes, 155; children, 681, 684; and chronic abdomen, 28; and cirrhosis, 160; classification of, 166; diagnosis, 4; and GI bleeding, 36–7, 409; and *H. pylori*, 149, 155–9, 162–4; heredity, 159–60; causing irritable bowel syndrome, 378; lesions, 153; NSAIDs, 28, 155; pain, 28; pathophysiologic defects in, 153t; pathophysiology of, 153–60; proton pump inhibitors, 164; role of pepsin, 155; treatment, 164; and vomiting, 11  
 peptidases, 200, 792, 798  
 peptide elongation, 784–5  
 peptide YY, 423  
 peptides, 71, 144, 200, 230, 234, 419, 450.  
*see also* specific types  
 Pepto-Bismol®, 218t  
 percussion: abdomen, 26, 44; for ascites, 47; liver, 45–6; spleen, 46  
 perforation: colon, 221, 344t, 391; esophagus, 134; free, 316t, 318; gallbladder, 471–2, 475; and lymphoma, 255; and NSAIDs, 160; of rectum, 402; small intestine, 216, 241, 249; stomach, 165; walled-off, 316t  
 perianal disease, 41, 292, 303, 315, 316t, 339–40, 410t, 413t  
 perianal mass, 398–9  
 perianal warts, 407  
 pericarditis, 547, 602t  
 pericholangitis, 316t, 344t, 346, 484  
 perifollicular hemorrhages, 205t  
 perifollicular papules, 205t  
 perifollicular petechiae, 203t  
 Peripheral Arterial Vasodilation Hypothesis, 613  
 peripheral edema, 23  
 peripheral neuritis, 235t  
 peripheral neuropathies, 23, 57t, 329  
 peristalsis: contractions, 93f; control mechanisms, 91–4; and GERD, 106; hypertensive, 118f; postsurgical, 102; primary, 90, 92f; secondary, 91  
 peritoneal irritation, 253  
 peritoneal metastases, 47  
 peritonitis: abdominal pain, 24–6; bile, 481; cholecystitis, 472; in Crohn's disease, 318; with ischemia, 264–5, 269, 270f, 279, 285; spontaneous bacterial, 620–3, 627  
 peroral dilation, 110, 127, 130, 133  
 personality changes, 624  
 perspiration, 9, 35  
 petechiae, 203t  
 pets, 22  
 Peyer's patches, 307–8  
 pH monitoring, 99, 100f, 108, 110, 123–4  
 pharmaceutical industry. *see also* clinical trials  
 pharyngeal constrictor muscles, inferior, 88  
 pharyngeal irritation, 72  
 phenacyclidine (PCP), 519t  
 phenobarbital, 529, 655  
 phenolphthalein, 226t, 232  
 phenothiazines, 12, 231, 582, 584  
 phenylalanine, 65t  
 phenylephrine, 252  
 phenylketonuria, 706t  
 phenytoin, 525, 525t, 582  
 phlebotomy, 65t  
 phlegmon, 434  
 phosphate, inorganic, 265  
 phospholipases, 192, 430, 471  
 phospholipids, 53, 192  
 phosphorus, 77, 204t, 208, 321  
 photodynamic therapy, 127, 130  
 photophobia, 203t, 319, 348  
 phototherapy, 729  
 physiotherapy, 454  
 phytates, 65t  
 phytobezoars, 173  
 phytonadione. *see* vitamin K1  
 pica, 207  
 pigment stones: composition, 460, 464–5; formation, 55t  
 pigmentation: and cholestasis, 595; in celiac disease, 235t; and jaundice, 30; in liver disease, 588; in malassimilation, 203t; and malnutrition, 23  
 pill-induced esophagitis, 95  
 pilonidal disease, 406–7  
 pinaverium bromide, 382t  
 pinworm, 393, 399  
 piroxicam, 161  
 plaques: colonic, 390; esophageal, 113–14, 295–6; gastric, 147; intestinal, 205t, 224, 272  
 Plummer-Vinson syndrome. *see* Paterson-Kelly (Plummer-Vinson) syndrome

- pneumatic balloon dilation, 122  
 Pneumocystis carinii, 291, 299  
 pneumonia, 26, 72, 97  
 polidocanol, 608  
 polyarteritis, 430t, 554  
 polyarteritis nodosa, 554  
 polycythemia vera, 253, 274, 275t, 276, 287, 659  
 polyethylene glycol solution, 19, 722  
 polyglutamates, 178–9  
 polymeric formulas, 71, 77  
 polymyositis, 117t, 520  
 polypectomy, 35t  
 polyps: adenomatous, 366–8, 367f; colonic, 366–8; and constipation, 18; fibrovascular, 126; gallbladder, 4789; gastric, 173; hyperplastic gastric, 152  
 porcelain gallbladder, 473, 480  
 porphyria cutanea tarda, 559  
 Portagen®, 212t  
 portal hypertension: about, 601; in alcoholic liver disease, 570–2 passim; and ascites, 33; bile duct disease, 481–2; and cirrhosis, 592; cirrhotic cardiomyopathy, 610–11; complications, 604–6; diagnosis, 606–7; etiology and pathophysiology, 602–6; and gastritis, 151, 606t; and GI bleeding, 34; and hepatitis, 566; causing ischemia, 274, 275t; in liver disease, 502t, 504; management, 607–10  
 portal venous stasis, 274  
 portopulmonary hypertension, 612  
 postcholecystectomy syndrome, 479, 485  
 posterior column degeneration, 58t  
 postvagotomy, 144t  
 potassium. *see also* H<sup>+</sup>/K<sup>+</sup>-ATPase; absorption, 360; depletion, 237, 348, 366, 451; causing diarrhea, 213t; causing esophagitis, 116; causing gastropathy, 151; inflammatory bowel disease, 64t; replacement, 77, 213t; secretion, 360  
 potassium chloride, 116, 151  
 pouchitis, 353  
 pre-albumin, 67  
 preaortic plexus, 396  
 Precision Isotonic Diet®, 212t  
 Precision LR Diet®, 212t  
 preclinical studies, 80–1  
 prednisone, 327, 343, 351, 593  
 pre-eclampsia, 654, 656–7  
 pregnancy. *see also* childbirth; biliary complications, 463, 464t, 477; and E. histolytica, 391; ectopic, 25, 320t; false, 16; and GERD, 107; and hepatitis, 542; and hyperamylasemia, 428, 434; and liver disease, 583, 651–7; termination, 657t; vitamin deficiency syndromes, 57t; and vomiting, 11  
 presyncope, 35, 165  
 probiotics, 382t, 575, 628  
 procainamide, 225  
 proclentia, 398, 400  
 procollagenase, 430  
 proctalgia fugax, 40–1, 397  
 proctitis: and bleeding, 337, 413t; clinical features, 407–8; and constipation, 17t, 18, 212, 386; in homosexual men, 292; radiation, 412; tenesmus, 397; treatment, 349, 351, 408  
 proctocolectomy, 353, 368, 484  
 proctocolitis, 399  
 proctosigmoiditis, 335, 351  
 proctosigmoidoscopy, 342t, 386–7, 401  
 proelastase, 430  
 proenzymes, 199, 430  
 Prograf®, 639  
 prokaryote cells, 789  
 prokinetic agents, 108, 382t  
 prolamins, 61  
 prolapse: rectal, 316t, 344t, 384, 398, 403, 455t, 721; uterine, 384  
 proliferative glomerulonephritis, 559  
 proline, 200, 789  
 propionate, 362  
 propionic acid, 199, 245  
 propranolol, 523t  
 proprioception, 207  
 propylthiouracil, 573  
 propylthiouracil, 582  
 prostaglandins: and carcinoid syndrome, 250; and cholecystitis, 471; causing diarrhea, 226t, 230; gastric role, 74; GI protection, 161; inhibitors, 231; and intestinal secretion, 190t, 231; to treat pancreatitis, 436; production, 144  
 protease inhibitors, 525t, 585  
 proteases, 199, 442  
 protein: absorption, 199–202; amylase, 195; and cystic fibrosis, 718, 721; deficiency, 203t–4t; in digestion, 50, 51f, 192, 230; in DNA replication, 756t; glycosylation, 799–801, 802f; heat-labile, 230; malabsorption, 721; malassimilation, 203–4t, 206; plasma, 66; post-translational processing, 787–9, 787–9; processing in endoplasmic reticulum, 795; replacement, 212t; restriction, 63; sorting and transport from Golgi apparatus, 801–6; synthesis,



740, 782–7; targeting, 790–5; transport from endoplasmic reticulum, 795–9; vesicular transport, 803–6

protein-energy malnutrition, 54t, 55–9, 203t–4t, 437, 701–3

protein-losing enteropathy, 23, 55, 64t, 68, 248–9, 302, 315t

proteinuria, 249

proteolysis, 52f, 56

Proteus, 621t

prothrombin, 494

prothrombin time (PT) test, 64, 208, 507, 572, 599, 601t

proton pump antagonists. *see* proton pump inhibitors

proton pump inhibitors, 7, 37, 109, 167, 695

proton pump mechanism, 150

protozoa, 219

pruritus: anorectal, 399; in bile duct disease, 484; children, 732, 735; and cirrhosis, 592; in gallbladder cancer, 480; and hookworms, 393; and jaundice, 31; in liver disease, 501, 502t, 529, 583, 592; and neoplasms, 486; and pancreatic diseases, 445; and pinworm, 393; in pregnancy, 655–6; with *Strongyloides stercoralis*, 299

pseudocyst, 16

pseudocyst, pancreatic, 434, 438, 439f–40f

pseudodiverticulum, 372

pseudolymphoma, 173

pseudolymphoma, gastric, 173

pseudomembranous colitis, 20, 223–4, 284, 320t, 390

*Pseudomonas* species, 718

pseudo-obstruction, 201t, 245t, 252

pseudopolyps, 344t

psoriasis, 399

psychological trauma, 10. *see also* stress

psychosis, in celiac disease, 235t

psychosocial factors: childhood RAP, 26; and diagnosis, 3–4; growth failure, 706t, 707; and HIV-infected patients, 306; liver transplantation, 635t

psyllium, 211t, 385, 404

pteroylglutamates, 178

pteroylglutamic acid. *see* folic acid

puborectalis muscles, 17, 40, 381, 395, 697

PUD. *see* peptic ulcer disease (PUD)

pulmonary infections, 101

purgatives, 389

purpura: and celiac disease, 235t; in gastroenteritis, 217; causing pancreatitis, 430t; skin, 205t; vitamin deficiency, 58t

pus in stool, 18, 20, 211, 231

Pustow operation, 442

pyelography, 27, 40

pyelonephritis, 25

pyloric sphincter, 144t

pyloric stenosis, 172

pyloromyotomy, 173

pyloroplasty, 144t

pylorus, 71, 244

pyoderma gangrenosum, 316t, 319, 335, 345t, 347–8

pyrazinamide, 293t

pyridoxine. *see* vitamin B6

pyridoxine-antagonist drugs, 57t

pyrimethamine, 294t

pyrosis. *see* heartburn

Questran®, 224

quinacrine, 31, 220, 297

quinacrine hydrochloride, 294t

quinidine, 213t, 225, 523t

RAD, 640

radiation colitis, 413t

radiation injury, 275t, 277f

radiography, 100, 106t, 510, 734

radiotherapy: anal carcinoma, 303; complications, 95, 116; esophageal neoplasms, 7, 127, 130; for gastric cancer, 171; and GI bleeding, 35t, 412; liver neoplasms, 648; pancreatic cancer, 449

Ramstedt's procedure, 173

ranitidine, 443, 724

Ranson's criteria, 431t, 432

RAP (recurrent abdominal pain). *see* pain, abdominal, children

Rapamune®, 640

rapamycin, 640, 643

rash: and carcinoid syndrome, 250; with hepatitis, 547; in parasitic infection, 299, 393; vesicular, 652

Raynaud's phenomenon, 95, 122, 592

recombinant DNA technology, role, 738–41

recombinant factor VII, 167

rectal examination, 165

rectal prolapse, 384

rectum: anatomy, 358; bleeding, 314, 315t, 318, 332–4, 342t, 365t, 380, 397–8, 403; neoplasms, 303, 398–9, 403; perforation, 402; prolapse, 316t, 344t, 384, 398, 403, 455t, 721; trauma, 382

reflexes, 204t

reflux, gastroesophageal. *see* GERD

reflux ileitis, 337, 338f

refractory sprue, 241

- regurgitation. *see also* GERD; vomiting;  
 about, 5–6; achalasia, 122; in esophageal  
 disorders, 95–6; nasal, 95; in Zenker's  
 diverticulum, 131
- rehydration therapy: cholecystitis, 472;  
 diarrhea, 225, 714t, 716; gastroenteritis,  
 214; nausea, 11; oral, 716
- renal calculi, 348
- renal colic, 29
- renal disease, 206, 317t
- renal failure: after liver transplantation, 638,  
 640–1; children, 715; chronic, 12, 144t,  
 160; and hepatorenal syndrome, 629, 631;  
 with ischemia, 253; in liver disease, 502t,  
 540, 544, 552, 586, 600, 617, 627, 635;  
 nutritional intervention, 73; and  
 pancreatitis, 429t, 434
- renal function disturbances, 327
- renal insufficiency, 427t
- renal stones, 25, 206
- renin-angiotensin system, 263
- reovirus, 213t
- reperfusion injury, 264
- research: clinical trials, 81–2; Declaration of  
 Helsinki, 79, 86; ethical concerns, 79, 85;  
 methodology, 82–3; monitoring, 85;  
 preclinical studies, 80–1; regulations,  
 79–80
- resection: bowel, 271, 273–4; colon, 374;  
 gastric, 149, 152; hepatic, 491, 574, 644,  
 647–8; ileal, 201t, 243;  
 pancreatoduodenal, 449; small intestine,  
 144t, 242–3, 254, 317
- respiratory failure, 434
- resuscitation, of ischemic patient, 269, 270f
- retching, 5, 97, 134
- reticulin, 237
- reverse transcriptase inhibitors, 291
- rheumatoid arthritis, 275t, 347, 591–2, 645
- rhinitis, allergic, 114
- ribavirin, 304, 540, 562t–3t, 564, 565t
- riboflavin. *see* vitamin B2
- ribonucleases, 420
- ribonucleic acid (RNA): classification, 741;  
 degradation, 777–8, 779f; and DNA  
 mutations, 759–64; in DNA replication,  
 740, 755–9; editing, 776, 778f; post-  
 transcription processing, 764–80;  
 processing, 772–4; promoter selection,  
 778–80; and protein synthesis, 740, 782–7;  
 splicing mechanisms, 774–6; structure,  
 741; as template for DNA, 740;  
 transcription, 739–40, 743; translation,  
 740, 747, 760t, 774, 782–7
- ribosomal RNA: role, 742; transcription,  
 739–40; translation, 740
- ribosomes, 483f, 742
- ricketts, 205t, 206–7
- rifabutin, 293t, 295
- rifampicine, 523t
- rifampin, 293t, 592, 655
- rigidity, 624
- rings, esophageal, 130–1
- ritonavir, 291
- RNA. *see* ribonucleic acid (RNA)
- Rome II criteria, 377
- rotavirus, 213t, 218–19, 711
- Rotor's syndrome, 528t, 530
- roundworms, 219, 392
- Roux-en-Y anastomosis, 482
- rRNA. *see* ribosomal RNA
- rubber-band ligation, 404
- rumination, 96
- rupture, gastric, 172
- sacroiliitis: Crohn's disease, 319;  
 inflammatory bowel disease, 316t, 347
- s-adenosylmethionine, 655
- Salazopyrin\*, 349
- salicylates, 429t
- Salmonella, 320t; causes, 389; causing  
 diarrhea, 213, 216–18, 712; HIV-  
 associated, 292, 293t; treatment, 389–90;  
 with ulcerative colitis, 336, 341t
- salmonellosis, 217
- Salofalk®, 349–50
- Sandifer's syndrome, 694t
- saquinavir, 291
- sarcoidosis, 148t, 151, 602t
- satiety center, 12
- scalene node biopsy, 130
- Schatzki's ring, 7, 131, 134
- Schilling test, 245, 248, 321, 426
- schistosomiasis, 341t, 602t
- scintigraphy, 451, 466, 468, 470, 472, 474
- scleral icterus, 31, 527
- scleral injection, 319
- scleroderma: causing bacterial overgrowth  
 syndrome, 245t; causing diarrhea, 226;  
 esophageal, 95, 97, 119, 122–3; and  
 GERD, 108; and malassimilation, 201t;  
 parenteral nutrition, 76
- sclerosing cholangitis, 64, 335–6, 344t, 346,  
 483–5, 593f, 594, 597, 598t
- sclerosis, 484, 572, 602t
- sclerotherapy, 608
- scorpion venom, 430t
- scratch test, 45

- scurvy, 58t  
 seborrhea, 203t, 205t  
 secondary iron overload, 586  
 secretagogues, 226t, 231  
 secretin, 144–5, 419  
 secretion: basal, 423; in colon, 360; of  
   enzymes, 419–21; gastric, 143–5; in  
   pancreas, 418–19; ; postprandial, 423;  
   regulation of, 423; rotavirus-induced, 712;  
   in small intestine, 230–1  
 seizures, 207, 216, 624  
 selenium, 56, 579  
 senecio alkaloids, 55t  
 Sengstaken-Blakemore tube, 607  
 senna, 19, 232  
 sepsis, 75, 77, 274, 275t, 276, 474, 477, 641  
 Septata intestinalis, 298  
 serotonin, 190t, 231, 292t, 358  
 serotonin antagonists, 250, 525t  
 serum biochemical tests, 27  
 serum immunologic tests, 507–11  
 sex factors: Caroli's disease, 480;  
   cholelithiasis, 464t; colorectal cancer, 369;  
   Condylomata acuminata, 407; constipation,  
   385; Crohn's disease, 311t; esophageal  
   cancer, 127–8; fecal incontinence, 374,  
   383; Gilbert's syndrome, 527;  
   hemochromatosis, 588; hepatitis B, 558;  
   hepatosplenomegaly, 723;  
   hyperbilirubinemia, 527; inflammatory  
   bowel disease, 311t; irritable bowel  
   syndrome, 379; liver disease, 531, 556,  
   559t, 562, 566–7, 571, 588, 655; liver  
   neoplasms, 644, 646; nutrition, 69;  
   pancreatic cancer, 443; pancreatitis, 437;  
   pelvic floor dyssynergia, 388; pilonidal  
   disease, 407; proctalga fugax, 40; PUD,  
   163; pyloric stenosis, 172; rectal prolapse,  
   398; sclerosing cholangitis, 483; ulcerative  
   colitis, 311t, 334  
 sexual activity, 290, 535t, 551t, 558, 565,  
   599  
 sexual orientation, 290. *see also*  
   heterosexuality  
 sexually transmitted disease (STD), 399,  
   407–8. *see also* HIV  
 shifting dullness, 33  
 Shigella dysenteriae: causes, 388; causing  
   diarrhea, 213t, 215, 218, 712;  
   gastroenteritis, 215; and HIV, 292, 293t;  
   treatment, 388–9; with ulcerative colitis,  
   336, 341t  
 shock: in GI bleeding, 409; with ischemia,  
   265; and pancreatitis, 432, 434;  
   pseudomembranous colitis, 224  
 shock liver, 506  
 short bowel syndrome, 71, 76–7, 194, 198,  
   242–3, 706t  
 short-chain fatty acids, 195, 197, 228, 245,  
   324, 625  
 Shwachman syndrome, 706t  
 sicca syndrome, 591–2  
 sickle cell disease, 275t, 276, 389–90  
 sigmoidoscopy, 18, 22, 224, 297, 300, 321,  
   337, 380, 386, 404  
 simethicone, 382t  
 Simulect®, 640  
 sinus tract formation, 113  
 sinusitis, 72  
 sinusoidal lining, liver, 493  
 sitophobia, 64t  
 skin: atopy, 114; with carbohydrate  
   malassimilation, 203t; carcinoid syndrome,  
   250; and dysphagia, 95; with inflammatory  
   bowel disease, 316t; telangiectasia, 165;  
   with ulcerative colitis, 347; vitamin  
   deficiencies, 205t; xanthoma, 482  
 skin tags, 398, 402, 405  
 sleep disturbances, 107, 225, 380, 624, 683  
 small bowel disease, 20, 317–18  
 small for gestational age, 704  
 small intestine: absorption of carbohydrates,  
   194–9; absorption of electrolytes, 185–92;  
   absorption of fat, 192–4; absorption of  
   protein, 199–202; absorption of vitamins  
   and minerals, 178–83; absorption of water,  
   183–5; absorption principles, 178;  
   anatomy, 175–7; bacterial overgrowth,  
   246–8; biopsies, 238–40; disaccharidase  
   deficiencies, 232–4; flora, 244–6;  
   idiopathic pseudo-obstruction, 252;  
   malassimilation, 202–9; Meckel's  
   diverticulum, 249–50; motility, 177–8,  
   228; neoplasms, 250, 255; protein-losing,  
   248–9; Whipple's disease, 250  
 small nuclear RNA, 743  
 small vessel disease, 275t; 277t  
 small-cell carcinoma, esophageal, 126t  
 smoking: gastric cancer, 168; NSAIDs, 160t;  
   pancreatic cancer, 444; PUD, 155, 163  
 snRNA. *see* small nuclear RNA  
 socioeconomic status, 128  
 sodium: absorption, 186, 187f–8f, 197; and  
   protein absorption, 201–2; reabsorption,  
   617; restriction, 63  
 sodium bicarbonate, 172  
 sodium citrate, 227t  
 sodium phosphate, 227t

- sodium pump, 185, 187, 197, 360  
sodium sulfate, 227t  
soiling, 352, 386–7, 696–7, 700  
somatostatin: to treat diarrhea, 231; in digestion, 145; electrolyte secretion effects, 190, 192; to treat islet cell tumors, 451; and pancreatic diseases, 423; to treat pancreatitis, 442; to treat portal hypertension, 607  
somatostatinomas, 451  
sorbitol, 19, 21t, 225, 227t, 701, 702t  
speech pathologists, 118  
sphincter of Oddi dysfunction, 479  
sphincteroplasty, 151, 452  
sphincterotomy: AIDS cholangiopathy, 304; for anal fissures, 406; for choledocholithiasis, 475–6; and fecal incontinence, 384; for pancreas divisum, 452; for pancreatitis, 435; for postcholecystectomy syndrome, 479  
spider angiomas, 651  
spider nevi: in alcoholic liver disease, 570–1; in hepatitis, 566; in jaundice, 31; in liver disease, 502t  
spider telangiectasia, 624  
spinal cord degeneration, 207, 235t  
spinal cord lesion, 217t  
spiramycin, 222, 298  
spironolactone, 33, 188, 617  
splanchnic circulation, 260–5, 630  
spleen: and ascites, 33; enlarged. *see* hepatosplenomegaly; splenomegaly; examination of, 46–7  
splenomegaly: and alcoholic liver disease, 571; in cirrhosis, 600; investigating, 38; in liver disease, 543; and portal hypertension, 602t, 606; and portal vein thrombosis, 661  
spondylitis, 319, 335, 347  
spontaneous bacterial peritonitis, 615t, 620–3, 627  
sprue: celiac. *see* celiac disease; collagenous, 201t, 241, 242f; refractory, 241; tropical, 198, 201t, 239, 241  
squamous cell carcinoma, esophageal, 115, 125–8,  
squamous cell papilloma, esophageal, 125  
Standard Vivonex®, 212t  
Staphylococcus aureus, 213–14  
staphylococcus aureus, 341t  
starch, 50, 194–5, 198  
starvation, 54, 57t  
STD. *see* sexually transmitted disease (STD)  
steatohepatitis. *see* fatty liver  
steatorrhea. *see also* fat; malabsorption; and bacterial overgrowth, 246, 248; biliary atresia, 482; and celiac disease, 236–7; clinical features, 424; with Crohn's disease, 315t, 323; cystic fibrosis, 454, 456; and diarrhea, 226, 228, 231, 321; dietary therapy, 59–60; and malassimilation, 209; and malnutrition, 22–3; and pancreatitis, 424–5, 437, 441–2; and parasitic enteritis, 219; and short bowel syndrome, 243  
steatosis, 55t, 457, 509, 569, 571, 575–8 passim, 654, 656  
stenosis: and enteral nutrition, 72; esophageal, 103; papillary, 304; pyloric, 172  
stents, 127, 130, 133, 442, 475, 486, 573  
sterculia, 385  
steroids, 64t, 114, 391, 394–5, 429t, 573, 655  
stomach: abdominal mass, 39; anatomy, 138–41; function, 143–5; gastritis, 145–53, 145–53; hemorrhage, 164–8; motility, 142–3; neoplasms, 168–71; physiology, 142–5; postgastrectomy problems, 244; PUD, 153–60, 162–4; role in digestion, 180  
stomatitis: angular, 58t, 203t, 207; with carbohydrate malassimilation, 203t; and islet cell tumors, 450; with ulcerative colitis, 335  
stool: blood in, 18, 20, 33, 35–6, 165, 211, 216–17, 231, 285, 333, 336, 366, 386, 390, 683, 713, 715; changes in, 377; color, 35–6, 503, 732; consistency, 16, 19, 211, 377, 697, 713; fatty acids. *see* steatorrhea; frequency, 16, 19–20, 35, 209, 212, 218, 224, 333, 342, 378–9, 384–5, 696; with malassimilation, 204; mucus in, 377–9, 399; pus in, 18, 20, 211, 231; straining at, 16, 378, 397, 402–4 passim, 696; volume of, 19–20, 185, 209, 211–12, 216, 228, 231, 333, 717  
straining at stool, 16, 378, 397, 402–4 passim, 696  
strawberry gallbladder, 478  
Streptococcus species, 244  
streptokinase, 271–2, 287  
streptomycin, 293t  
streptozocine, 450  
stress. *see also* psychological trauma; and gastritis, 151; globus, 4; heartburn, 6; RAP, 682, 685; vomiting, 690  
stress erosions, 34  
stress hormones, 53  
strictures: and bacterial overgrowth

- syndrome, 245t; biliary, 346, 439, 485; colonic, 344t, 346; with Crohn's disease, 322, 342t, 373, 376; causing diarrhea, 226t; esophageal, 105, 113–14, 116; fibrous, 316t; with ischemic colitis, 287; postischemic, 376; postsurgical, 376; small intestine, 201t, 222, 279f; with ulcerative colitis, 342t
- stricturoplasty, 287
- stridor, 115
- string sign, 310f
- stroke, 26
- Strongyloides stercoralis, 213t, 299, 393–4
- subacute bowel obstruction, 28
- subacute combined degeneration, 57t
- subjective global assessment (SGA), 68, 69t
- substance P, 145, 190t
- substrates, 49, 53, 525
- succinylsulfathiazole, 246
- succussion splash, 72
- sucrase-isomaltase, 196
- sucrose: absorption, 194; deficiencies, 232; dietary therapy, 65t
- sugars, 189, 195, 197, 238, 246, 357, 362–3, 711, 717, 801
- sulfapyridine: digestion, 246; to treat inflammatory bowel disease, 349
- sulfasalazine, 64t, 245, 325t, 347, 349
- sulfathiazole, 246
- sulfonamides, 305, 329, 429t, 582
- supraclavicular lymphadenopathy, 97, 128
- suprahyoid muscles, 91
- surgery: abdominal aneurysm, 26; acute abdomen, 24, 26; AIDS cholangiopathy, 304; anal fissures, 406; antireflux, 14, 109–12, 122; Barrett's esophagus, 112; bile duct disease, 480, 482–3, 486; biliary atresia, 731; gastric cancer, 170–1; cholecystectomy, 469; cholecystitis, 472; choledochal cysts, 481; cholelithiasis, 389, 473; chronic abdomen, 30; colon cancer, 364, 366; colonic obstruction, 375, 377; Crohn's disease, 330–1; cystic fibrosis, 456–7, 719; diverticula, 131, 133; dysphagia, 123; esophageal fistulas, 102; esophageal neoplasms, 7, 125, 127, 130; esophageal trauma, 134; fecal incontinence, 384; gallbladder neoplasms, 480; gastric, 151, 153, 167, 173; GERD, 108–9, 111–12, 695; GI bleeding, 167; hemorrhoids, 403; hiatus hernia, 103; Hirschsprung's disease, 387; intestinal bypass, 551t; ischemia, 253–4, 266, 271–3 passim; ischemic colitis, 286–7; islet cell tumors, 450; liver neoplasms, 648; liver transplant. *see* liver transplantation; Mallory-Weiss tear, 134; meconium ileus, 456; pancreatic, 208t, 442, 449, 452; peritonitis, 269; pilonidal disease, 407; polyps, 368; for portal hypertension, 608; post-radical neck, 117t; small bowel obstruction, 317; ulcerative colitis, 343, 345, 352–3
- swallowing: difficulty. *see* dysphagia; pain. *see* odynophagia
- sweat clorides, 457
- sympathectomy, 192
- sympathetic afferents, 11f
- syncope, 35
- synechiae, 348
- synovitis, 347
- syphilis, 149–50, 292, 303, 341t, 405, 407–8
- systemic mastocytosis, 160
- systemis sclerosis, 17
- tabes dorsalis, 117t
- tachycardia: and acute abdomen, 26; and alcoholic liver disease, 570; cholecystitis, 472; with cirrhotic ascites, 614; and GI bleeding, 36; and pancreatitis, 432; with toxic megacolon, 340, 345t; and ulcerative colitis, 333; with vomiting, 9
- tachypnea, 26
- tacrolimus, 525t, 639, 641
- tamoxifen, 576
- tannins, 65t
- tapeworms, 219
- tattoos, 551t, 599
- taurine, 245, 457
- tegaserod, 19, 382t
- telangiectasia, 624
- telomeres, 747, 758–9
- tenesmus: and diarrhea, 211, 232, 388; with lesions, 397; with prolapse, 398; with ulcerative colitis, 351
- terlipressin, 607
- testicular atrophy, 502t
- testosterone, 573
- tetany: and celiac disease, 235t, 236; and malabsorption, 207; and malassimilation, 204t
- tetracycline: to treat bacterial overgrowth, 248; to treat Crohn's disease, 329; to treat HIV-related infections, 293t; to treat infection, 392; causing pancreatitis, 429t; to treat STDs, 408
- thalassemia, 589
- the flux. *see* diarrhea

- thenar mass reduction, 206  
 theophylline, 525t  
 Therapeutic Product Division, Health Canada, 81  
 thiabendazole, 299, 394  
 thiamine. *see* vitamin B1  
 thiazolidinediones, 579  
 thoracic rosary, 203t  
 3TC, 291, 304. *see also* lamivudine  
 thrombocytopenia, 304, 502t, 504, 547, 572  
 thrombocytosis, 317t, 321, 344t, 347, 659  
 thromboembolic disease, 344t  
 thrombolytic therapy, 271–2, 660  
 thrombophilias, 653  
 thrombophlebitis, 445  
 thrombosis: with catheter embolization, 75;  
 of hemorrhoids, 403; hepatic, 626t, 638, 641, 659; inferior vena cava, 659; and ischemia, 274; mesenteric, 243, 252, 274, 347, 433; and pancreatitis, 433t, 434; perianal, 397, 403; portal, 464, 602t, 604, 626t, 661; postsurgical, 640–1; splenic, 602t; superior vena cava, 619; treatment, 254; of varix lumen, 608; venous, 254  
 thrush, oral, 113  
 thymine, in gene sequences, 741  
 thymoglobulin, 639  
 thyrocalcitonin, 190t  
 thyroid disease, 231  
 thyroiditis, 559, 591  
 TNM staging system, 170, 365  
 tobacco use. *see* smoking  
 Todani classification, 481  
 tolbutamide, 523t, 525t, 527  
 toluene, 519t  
 tomography, computed, 509  
 tongue, 203t, 207  
 total parenteral nutrition (TPN), 70, 73, 212t, 252, 286, 324, 349, 455, 464t, 478, 576  
 toxoplasmosis, 291  
 TPN. *see* total parenteral nutrition (TPN)  
 tracheoesophageal fistula, 72, 101–3  
 tranexamic acid, 167  
 trans-acting factors, 767–9  
 transaminases, 129, 505–6. *see also* aminotransferases  
 transcobalamin II, 182t  
 transcription: alternative polyadenylation sites, 780; and chromatin structure, 764–5; cis-acting elements, 764–7, 769; defined, 747; initiation, 769–71; promoter selection, 778–81; regulation, 771; RNA degradation, 777–8, 779f; RNA editing, 776, 778f; splicing mechanisms, 774–6; trans-acting factors, 767–9  
 transection, esophageal, 91  
 transfer RNA: role of, 742, 782;  
 transcription, 739, 772; translation, 740  
 transjugular intrahepatic portosystemic (TIPS) shunt, 573–4, 608, 620, 629, 632, 660–1  
 translation: defined, 747; process, 782–7; regulation, 787  
 transplantation: bone marrow, 115; ethics, 574; indications, 601; kidney, 640; liver. *see* liver transplantation  
 Traube's space, 46  
 trauma: acalculous cholecystitis, 477; anal, 303; anorectal, 382; esophageal, 133–4; gastric, 148t; neurological, 160; rectal, 292; small bowel, 243; surgical, 384  
 Travasol®, 212t  
 Travasorb STD®, 212t  
 travel: diarrhea risk, 20, 218, 713, 715; hepatitis risk, 533, 535, 542; Shigella risk, 388  
 travel history, 399  
 traveler's diarrhea, 20, 218  
 trehalose, 232  
 trematodes, 219  
 Treponema pallidum, 408  
 trichloroethylene, 408t  
 trichobezoars, 173  
 trichuris, 213t  
 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, 86  
 tricyclic antidepressants, 125  
 triglycerides. *see also* fat; 71, 143, 193;  
 lipolysis of, 192; malabsorption, 208t; maldigestion, 23; malnutrition, 55, 60; and protein-losing enteropathy, 249; replacement, 212t; role in digestion, 53; role of liver, 494  
 trimebutine, 382t  
 trimethoprim-sulfamethoxazole: to treat colonic infection, 389; to treat HIV-related infections, 293t–4t, 299; to treat peritonitis, 623; to treat Whipple's disease, 251  
 tRNA. *see* transfer RNA  
 trophozoites, 221, 391  
 Trousseau's sign, 207  
 Trypanosoma cruzi, 122  
 trypsin, 56, 199, 234, 420, 430  
 trypsinogen, 199, 420, 426  
 tryptophan, 245  
 tube feeding. *see* enteral nutrition  
 tuberculosis, 320t, 321  
 tubulovesicles, 366, 368

- tumors. *see* neoplasms  
 Turcot's syndrome, 368  
 tylosis, 126, 128t  
 tympany, 16, 340  
 tyrosine, 65t  
 tyrosinemia, 65t, 597, 598t
- UDP-glucuronyl transferase, 527, 529  
 UES. *see* esophageal sphincter, upper  
 ulceration: aphthous, 308, 309f, 316t, 321; of colon, 391; with Crohn's disease, 308; with cytomegalovirus, 300; deep, 105, 112; duodenal, 34, 155, 156f, 158f, 159–60, 162–4; with *Entamoeba histolytica*, 221; esophageal, 114, 116, 295, 301; flask-shaped, 297; gastric, 34, 152, 155, 162–3; with ischemic colitis, 285; mucosal, 134; and NSAIDs, 160; rectal, 320t, 410t, 413t; in ulcerative colitis, 331  
 ulcerative colitis: about, 331; children, 712; chronic diarrhea, 21t, 226t; clinical features, 332–5; and colon cancer, 369; complications, 340–8, 344–5t; diagnosis, 335–9; dietary therapy, 62; manifestations of, 316t; pathophysiology, 331–2; rectal bleeding, 380; resembling Crohn's disease, 320t, 321; treatment, 348–53  
 ultrasonography, 508–10  
 ultraviolet light, 592  
 undifferentiated carcinoma, esophageal, 126t  
 United States, drug research, 80  
 upchuck. *see* vomiting  
 uracil, in gene sequences, 742, 762–3  
 urea, 36, 245  
 uremia, 11  
 urination, frequent, 379  
 urine, color, 474  
 urobilinogen, 245, 503  
 urokinase, 271–2, 287, 660  
 ursodeoxycholic acid, 457, 469, 484, 579, 593, 655, 723, 735  
 urticaria, 393  
 uterine prolapse, 384  
 uveitis, 316t, 319, 335, 345t
- vacA gene, 162  
 vacuolating cytotoxin gene (vacA), 162  
 vadodilators, 263, 287  
 vagal afferents, 11f  
 vagal cholinergic reflex, 5  
 vagotomy: and cholelithiasis, 464t; complications, 172; malabsorption, 193  
 vagovagal reflex, 97, 106  
 vagus nerves, 89, 143, 359, 417, 423  
 valacyclovir, 294t, 301  
 valproic acid, 429t  
 Valsalva's maneuver, 252  
 vanadium, 56  
 vancomycin, 224, 390  
 vanishing duct syndrome, 584  
 variceal bleeding, 34, 37, 457, 599–600, 604–6, 653  
 variceal dilation, esophagus, 89  
 varicella, 429t  
 vasculitis, 275t, 276, 287, 320t, 430t, 547, 591, 645  
 vasoactive intestinal peptide-secreting tumors, 451  
 vasoactive intestinal polypeptide (VIP): causing diarrhea, 19; and pancreatic secretion, 423  
 vasoconstrictors, 253, 263, 276, 607  
 vasopressin, 190t, 263, 607  
 vasospasm, 264, 269, 271–2  
 venereal disease. *see* sexually transmitted disease (STD)  
 venereal warts, 398  
 veno-occlusive disease, 602t, 660  
 verapamil, 275t, 280, 523t  
 vibration sense, 23, 204–5, 207  
*Vibrio cholerae*, 19, 213t, 214, 226t, 230, 712  
*Vibrio parahaemolyticus*, 213t, 215, 341t  
 videocapsule imaging, 208  
 villous atrophy, 60t  
 vinyl chloride, 585  
 Viokase®, 211t  
 VIP. *see* vasoactive intestinal polypeptide (VIP)  
 VIPomas, 451  
 viral hepatitis, 32, 429t, 530–65, 547t, 566t, 597, 598t. *see also* specific types  
 virologic response, 562, 564f  
 viruses: causing diarrhea, 213t, 219; causing esophagitis, 113; HIV-associated, 294t, 300–2; RNA, 747  
 visceral nociception, abnormal, 125  
 viscus, perforated, 27  
 vitamin A: to treat cystic fibrosis, 455; deficiency, 58t, 60t, 64, 203t, 205t, 206, 235t, 455; causing liver disease, 584; replacement, 210t  
 vitamin B1 deficiency, 23, 57t, 77, 204t–5t, 235t  
 vitamin B2 deficiency, 57t, 203t  
 vitamin B6, 235t  
 vitamin B6 deficiency, 23, 57t, 203t, 205t  
 vitamin B12: absorption, 143, 180–3; and

- bacteria, 245; and Crohn's disease, 324; deficiency, 57t, 59, 60t, 182, 204t–5t, 206–8, 235t, 237, 321; dietary therapy, 62; malabsorption, 246, 315t; malnutrition, 23, 56; and pancreatitis, 443; and R factor, 426; replacement, 210t
- vitamin B deficiency, 23, 56
- vitamin C deficiency, 58t, 203t–5t
- vitamin D: deficiency, 58t, 64, 203t–5t, 235t, 455; dietary therapy, 62; inflammatory bowel disease, 64t; malabsorption, 206–7; supplements, 592
- vitamin D2, 210t
- vitamin E: deficiency, 58t, 64, 206, 235t; to treat nonalcoholic liver disease, 579; replacement, 210t
- vitamin K: bacteria, 245; bacterial overgrowth syndrome, 247; bioavailability, 494; deficiency, 58t, 64, 203t, 205t, 206, 235t, 237, 721; dietary therapy, 60; inflammatory bowel disease, 64t; in liver disease, 504; supplements, 655
- vitamin K1, 210t
- vitamin K3, 210t
- vitamine E, 60t
- vitamins: absorption, 178–83; deficiencies, 23, 56, 57t, 60t, 570, 720; dietary therapy, 60, 62
- vittiligo, 591
- VLDL, 53, 55
- volvulus, 28, 172, 243, 376t, 377
- vomit, blood in, 33, 36
- vomiting. *see also* regurgitation; about, 9–12; and acute abdomen, 25; alcoholic hepatitis, 570; and biliary colic, 467t; Boerhaave's syndrome, 134; causes, 687t; children, 684–5, ; cholecystitis, 167t, 471; cyclic, 690; and diarrhea, 214–16, 219; and diverticulitis, 373; fatty liver, 656; gastric volvulus, 172; and gastritis, 146–7; GERD, 110, 691; and hepatitis, 531, 542; and hookworms, 393; inflammatory bowel disease, 64t; investigation, 689–90; with ischemia, 253; and malnutrition, 23; management, 691; and nasenteric feeding, 73; nausea, 393; and pancreatitis, 77, 432; in pregnancy, 654, 656; and protein deficiency, 206; with small bowel obstruction, 318; symptoms and signs, 688t
- vomiting center, 10, 11f
- von Hippel-Lindau disease, 450
- Von Meyenberg's complexes, 482
- VSL#3, 353, 382t
- warfarin, 58t, 523t, 525, 525t
- warts, anal. *see* Condylomata acuminata
- wasting syndrome, 305–6
- water: absorption, 183–5; contaminated, 22; in gastric juice, 143; loss in feces, 199, 211; secretion, 712
- waterbrash: about, 5; in esophageal disorders, 96; with GERD, 107; with vomiting, 9
- weakness: and celiac disease, 235t; and cirrhosis, 599; and GI bleeding, 35; and iron deficiency, 207; with malassimilation, 204, 204t; with pancreatic diseases, 445; and protein deficiency, 206
- webs, esophageal, 130–1, 207
- weight, children, 705–7
- weight loss: and alcoholic liver disease, 570; with carbohydrate malassimilation, 203t, 204; and celiac disease, 235t, 236; and cholelithiasis, 464t; and cirrhosis, 599; and constipation, 18; with Crohn's disease, 314, 315t, 339; diagnosis, 3; causing diarrhea, 20, 211; dysphagia, 95; gastritis, 147; with GERD, 107; with HIV, 291–2, 296, 303, 305–6; inflammatory bowel disease, 38; with irritable bowel syndrome, 380; and ischemia, 274; and liver cancer, 647–8; in liver disease, 501, 502t; and lymphoma, 255; and malassimilation, 207, 209; and malnutrition, 23, 66; and nonalcoholic liver disease, 576, 578; and pancreatic diseases, 445; and pancreatitis, 438; and squamous cell carcinoma, 128; with Strongyloides stercoralis, 299; with ulcerative colitis, 334, 339; in Whipple's disease, 251
- Werner-Morrison syndrome, 451
- Wernicke's encephalopathy, 205t
- Wernicke-Korsakoff syndrome, 57t, 205t
- wheezing, 97, 107, 250
- Whipple's disease: about, 250–1; chronic diarrhea, 21t; and Crohn's disease, 151; and fat malabsorption, 193; and islet cell tumors, 450; and MAI, 292; malassimilation, 201t; therapy, 208t
- whipworm, 393
- Wilson's disease: about, 518, 585–6; causing cirrhosis, 597; and cirrhosis, 598t; dietary therapy, 65t; causing dysphagia, 117t; causing hepatitis, 530t, 551t
- wind. *see* gas
- World Medical Assembly, 79
- xanthelasma, 501, 502t, 592, 595
- xanthogranulomatous gastritis, 151



- xanthoma, 482, 501, 502t
- xenotransplantation, 643
- xeroderma, 58t
- xeroderma pigmentosum, 764
- xerophthalmia, 58t
- xerosis, 203t, 205t
- x-ray. *see* barium x-ray
- Xylocaine®, 114
  
- Yersinia enterocolitica*, 213t, 216, 341t, 712
- Yersinia* species, 320t
  
- Zenapax®, 640
- Zenker's diverticulum, 7, 117t, 118, 131–2
- zidovudine. *see* AZT
- zinc: absorption, 63; deficiency, 203t, 205t, 628; and diarrhea, 23; inflammatory bowel disease, 64t; and malnutrition, 56; replacement, 210t; Wilson's disease, 65t
- Zollinger-Ellison syndrome: associated conditions, 180; and celiac disease, 239; chronic diarrhea, 21t; and Crohn's disease, 320t; and gastric folds, 152; causing gastritis, 148t; and intestinal secretion, 231; islet cell tumors, 450; and liver cancer, 649; malabsorption, 193
- zygomycosis, 150
- zymogen granules, 56, 420